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Cardioaortic embolism to the brain accounts for approximately 15–30% of ischaemic strokes and is often referred to as ‘cardioembolic
stroke’. One-quarter of patients have more than one cardiac source of embolism and 15% have significant cerebrovascular atherosclerosis.
After a careful work-up, up to 30% of ischaemic strokes remain ‘cryptogenic’, recently redefined as ‘embolic strokes of undetermined
source’. The diagnosis of cardioembolic stroke remains difficult because a potential cardiac source of embolism does not establish the
stroke mechanism. The role of cardiac imaging—transthoracic echocardiography (TTE), transoesophageal echocardiography (TOE), car-
diac computed tomography (CT), and magnetic resonance imaging (MRI)—in the diagnosis of potential cardiac sources of embolism, and
for therapeutic guidance, is reviewed in these recommendations. Contrast TTE/TOE is highly accurate for detecting left atrial appendage
thrombosis in patients with atrial fibrillation, valvular and prosthesis vegetations and thrombosis, aortic arch atheroma, patent foramen
ovale, atrial septal defect, and intracardiac tumours. Both CT and MRI are highly accurate for detecting cavity thrombosis, intracardiac
tumours, and valvular prosthesis thrombosis. Thus, CT and cardiac magnetic resonance should be considered in addition to TTE and TOE
in the detection of a cardiac source of embolism. We propose a diagnostic algorithm where vascular imaging and contrast TTE/TOE are
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considered the first-line tool in the search for a cardiac source of embolism. CT and MRI are considered as alternative and complemen-
tary tools, and their indications are described on a case-by-case approach.
...................................................................................................................................................................................................
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Ischaemic stroke is a major cause of disability and mortality world-
wide.1–4 Cardioaortic embolism to the brain accounts for approximate-
ly 15–30% of ischaemic strokes and is often referred to as
‘cardioembolic stroke’.5,6 Cardioembolic stroke is generally severe and
prone to early and long-term recurrences.7 Identifying potential cardiac
sources of embolism is a key objective, because treatment may vary
according to the cardiac condition diagnosed.8 Unfortunately, and often
despite comprehensive evaluation of the underlying cause, up to 30%
of ischaemic strokes remain ‘cryptogenic’ (i.e. without an established
cause).5,9 Consequently, a new entity has recently been defined: embol-
ic strokes of undetermined source (ESUS).10
The diagnosis of cardioembolic stroke is often difficult because the
presence of a potential cardiac source of embolism alone does not
establish the stroke mechanism. The clinical significance of minor or
uncertain sources of cardiac risk remains controversial,11 as reported
in the Canadian guidelines.12 Furthermore, approximately 25% of
patients have more than one cardiac source of embolism and 15%
have significant cerebrovascular atherosclerosis.13 Combined, these
clinical factors emphasize the role of cardiac imaging—transthoracic
echocardiography (TTE) and transoesophageal echocardiography
(TOE) as the first-line, and cardiac computed tomography (CT) and
magnetic resonance imaging (MRI) in addition—in the evaluation of
patients with stroke, in the diagnosis of potential cardiac sources of
embolism, and for therapeutic guidance.14,15
































































































Recommendations for classifying cardiac conditions that predis-
pose to cerebral embolism have been made previously,16 but we
strongly believe that the subject should be revisited based on new
imaging capabilities and evidence.
The need to update the
recommendations
Recommendations for the use of echocardiography in the diagnosis
and management of cardiac sources of embolism were published in
2010 by the European Association of Echocardiography (EAE).16 The
EAE recommends the use of TTE and TOE when neurological symp-
toms potentially due to a suspected cardiac cause are present.16 We
believe that an update is needed for the following reasons:
(1) The probability of detecting potentially emboligenic cardiac disease
depends on the diagnostic method used. Taking into account the
advances in ultrasound investigation techniques [real-time three-di-
mensional (3D) echocardiography—both TTE and TOE] and
the improved value of the other imaging modalities (CT and MRI),
we think it worthwhile to introduce herein these non-
echocardiographic techniques.
(2) ‘New’ potentially cardiac sources can be discussed [e.g. lef atrail sep-
tal pouch (LASP), atrial cardiomyopathy].17
(3) In the absence of evidence, clinical expertise recommends the use
of a synthetic algorithmic approach to cardiac work-up of a patient
with ischaemic stroke or transient ischaemic attack (TIA).
(4) Based on these recommendations, research projects could be con-
ducted to confirm and improve the level of evidence for performing
a diagnostic test or another investigation in the clinical context.
(5) The present recommendations do not deal with specific imaging
aspects related to exploration of the vessels. We focus instead on




Cerebral infarction is defined as brain, spinal cord, or retinal cell
death attributable to ischaemia, based on neuroimaging, neuropatho-
logical evidence, and/or clinical evidence of permanent injury.15
Transient ischaemic attack
TIA is a transient episode of neurological dysfunction caused by focal
brain, spinal cord, or retinal ischaemia, without acute infarction.15
Cryptogenic stroke
Cryptogenic ischaemic strokes are symptomatic cerebral infarcts for
which no probable cause is identified after adequate diagnostic evalu-
ation. More expansive definitions include strokes in patients who are in-
completely evaluated and in those with more than one probable
identified cause, defined according to the Trial of ORG 10172 in Acute
Stroke Treatment (TOAST) criteria.5,8 However, if the TOAST criteria
clearly specify that cryptogenic stroke is one that is not attributable to
known aetiologies, they do not indicate specific diagnostic modalities
that must be negative to declare a cryptogenic stroke.
More recently, the notion of cryptogenic embolism was intro-
duced in the Causative Classification of Stroke System.18 In this classi-
fication, cryptogenic embolism refers to a stroke for which there is
angiographic evidence of abrupt cut-off consistent with a blood clot
within otherwise angiographically normal-looking intracranial
arteries, or imaging evidence of complete recanalization of a previ-
ously occluded artery, or the presence of multiple acute infarctions
that have occurred closely related in time without detectable abnor-
malities in relevant vessels.
Embolic strokes of undetermined source
ESUS are defined as non-lacunar brain infarcts without substantial
proximal arterial stenosis or major cardioembolic sources, and ac-
count for 80–90% of cryptogenic ischaemic strokes.10 ESUS are
thought to be a therapeutically relevant entity, as antiplatelet therapy
and stroke risk-factor reduction are not highly effective in preventing
recurrent strokes. Criteria for the diagnosis of ESUS are described in
Supplementary data online, Table S1.
ESUS account for approximately one in six ischaemic strokes.
Patients with ischaemic stroke meeting the criteria for ESUS are relative-
ly young compared to patients with other ischaemic stroke subtypes,
and tend to have minor strokes consistent with small emboli. The retro-
spective methods used in the published studies limit confidence in pre-
dicting stroke recurrence rates, but indicate a substantial (>4% per
year) rate of stroke recurrence during (mostly) antiplatelet therapy.19,20
Several clinical and imaging findings suggest an embolic stroke:
a. abrupt onset of stroke symptoms;
b. previous infarctions in various arterial distributions;
c. multiplicity in space (infarct in both the anterior and posterior circula-
tion, or bilateral);
d. multiplicity in time (infarcts of different ages);
e. other signs of systemic thromboembolism (e.g. edge-shaped infarc-
tions of kidney or spleen; Osler splits; blue toe syndrome); and
f. territorial distribution of the infarcts involving the cortex, or subcor-
tical ‘large lenticulostriate infarct’.
Illustrations of patterns of brain infarctions signalling different
mechanisms of stroke are shown in Figure 1.16
Cardiovascular imaging tools
Transthoracic and transoesophageal
echocardiography for work-up of crypto-
genic stroke and stroke with a suspected
cardioembolic cause
TOE is a semi-invasive examination with possible associated compli-
cations but is widely performed in patients with ischaemic stroke.
TOE is consistently superior to TTE, particularly when the patient
presents without clinical signs suggestive of heart disease, but its su-
periority appears dependent on the patient’s age. Therefore, patient
age and history, and the risks of recurrence and consequences of
treatment must be considered when making a diagnosis of a cerebral
or peripheral embolic event. When a cardioembolic cause is sus-
pected, it is recommended to consider both TTE and TOE. TOE
should be performed according to the clinical context, but emergent
indications are limited (e.g. fever, prosthesis).8
A 2006 study reported that more than one in eight patients of any
age with normal TTE findings had a major cardiac risk factor revealed on
TOE that warranted anticoagulation.21 More than 30 cross-sectional











































































studies have evaluated the yield of TTE or TOE, or both, in detecting
cardiac sources of embolus in patients with stroke. In consecutive
patients, the yield of echocardiography for the detection of intracardiac
masses ranged from 0% to 21%.12 Pooled data from these studies sug-
gest an overall yield of 4% for TTE and 11% for TOE.
A systematic review and meta-analysis of 27 studies that aimed to as-
sess TOE for cryptogenic stroke revealed that TOE-detected findings
prompted the introduction of anticoagulant therapy in up to one-third
of patients.22 In a retrospective study that included 1458 patients hospi-
talized for stroke with a suspected cardioembolic cause, TOE changed
the management in approximately 16% of patients, leading to the intro-
duction of anticoagulation and antibiotics, closure and surgical closure
of patent foramen ovale (PFO), and coil embolization.14 In a meta-
analysis of 12 studies, the pooled rate of reported anticoagulation ther-
apy attributed to abnormal TOE findings among 3562 patients with
acute ischaemic stroke was 8.7% [95% confidence interval (CI) 7.3–
10.4]. The rates of initiation of anticoagulation therapy on the basis of
TOE investigation did not differ (P = 0.315) among patients with crypto-
genic stroke (6.9%, 95% CI 4.9–9.6), ESUS (8.1%, 95% CI 3.4–18.1), or
ischaemic stroke (9.4%, 95% CI 7.5–11.8).11
Computed tomography and magnetic
resonance imaging for work-up of crypto-
genic stroke and stroke with a suspected
cardioembolic cause
Both CT and MRI show potential for the detection of causes of cardi-
oembolic stroke.23 Indeed, both tests are highly accurate for detect-
ing left atrial appendage (LAA) thrombosis (LAAT) in patients with
atrial fibrillation (AF), with almost 100% sensitivity and specificity rela-
tive to TOE.24–27 CT also allows the identification of valvular pros-
thesis thrombosis, aortic atheroma, PFO,28,29 atrial septal defect,30
and intracardiac tumours.31 Cardiac magnetic resonance (CMR) is
more sensitive and accurate than TTE for the detection of intraven-
tricular thrombi after acute or chronic myocardial infarction (MI),32
and allows the detection of left ventricular (LV) thrombi in patients
with ESUS and a history of MI that may have been missed on TTE.33
Few studies have evaluated the sensitivity and accuracy of these
techniques in stroke, and the published literature is conflicting
(Supplementary data online, Table S2). In one study that included
patients with cryptogenic stroke undergoing TTE or TOE, CMR
reduced the percentage of patients classified as having cryptogenic
stroke after echocardiography, from 27% to 20%.34 However, in
other research, CMR had limited additional value over TOE35 and
failed to identify all potential cardioembolic sources identified by
TOE.36 CT has 89% sensitivity and 100% specificity for identifying
causes of cardioembolic strokes identified by TOE,37 and has a similar
predictive value as TOE for recurrence of ischaemic stroke.38
Combined use of CT and TTE/TOE was more sensitive than TTE/
TOE alone for detecting patients with at least one cardiac or aortic
high-risk finding after acute stroke,39 and in particular was able to
identify more cerebral infarcts. In contrast, CT alone was less suitable
for diagnosing small left atrial thrombi (LAT) or PFO than was TOE.
The main advantage of CT and MRI is that these tests are less invasive
than TOE. The main limitation of cardiac CT is radiation exposure.
However, when CT is already being performed in patients with acute
stroke for evaluation of the aortic arch and carotid arteries, extension of
the CT scan to the heart may be possible, allowing detection of high-risk
cardiac and aortic sources of embolism with no increased incidence of
contrast-induced nephropathy and only a minimal increase in radiation
exposure.40 Thus, CT and CMR should also be considered in addition
of TTE and TOE in the detection of a cardiac source of embolism.
Vascular imaging for work-up of crypto-
genic stroke and stroke with a suspected
cardioembolic cause
Approximately 25% of ischaemic carotid territory strokes are caused
by embolization from a ruptured plaque, or by an acute occlusion of
the internal carotid artery (ICA) or middle cerebral artery. The main
cause is atherosclerosis. Atherosclerotic stenoses are mostly located
at carotid bifurcations. There are other less frequent locations: bra-
chiocephalic trunk, common carotid arteries, intracranial arteries,
vertebral arteries, and middle cerebral artery. Approximately
10–15% of all ischaemic strokes are related to a previously
Figure 2 Carotid bifurcation with an echolucent ICA stenosis.
The aliasing shown by colour Doppler is a direct sign of severe ICA
stenosis. ICA, internal carotid artery.
Figure 1 Schematic drawings of patterns of brain infarctions sig-
nalling different stroke mechanisms.16 (A) Cardioembolic stroke is
probable in cortical infarcts with territorial distribution; (B) the
same holds true for large striatocapsular infarcts; (C) but not for la-
cunar infarctions, by definition located subcortically; and (D) low-
flow infarct can be located subcortical (left panel) or cortical (right
panel), but their distribution is interterritorial not territorial.






































asymptomatic ICA stenosis >50%,41 but ischaemic strokes can also
be preceded by TIA or fugax amaurosis.
Duplex ultrasound is considered as the first-line imaging modality
for carotid atherosclerosis. Unless they are too calcified, stenoses
can be evaluated by direct two-dimensional (2D) echo measure-
ments, colour Doppler (Figure 2), and optionally by Power Doppler,
eFlow, or B-flow.
Several methods can be used for 2D measurements of ICA sten-
oses.42 The standard method is the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) method, which is better
related to haemodynamics and CT or magnetic resonance (MR) angi-
ography. The European Carotid Surgery Trialists (ECST) method
gives a better assessment of plaque burden (Figure 3).
The NASCET and ECST methods measure diameter reduction.
Alone they are not sufficient to evaluate the degree of stenosis, espe-
cially for irregular or eccentric stenoses, and must be correlated with
Doppler velocities (see below). The area-reduction method can also
be used to measure ICA stenoses (Figure 4).
Of note, the ECST and area-reduction methods overestimate the se-
verity of the stenosis compared with the standard method (NASCET)
(Table 1). Their use must therefore be recorded in the patient’s files.42
CT and MR angiography may also be required. Their advantage is
the ability to give simultaneous imaging of the aortic arch, supra-
aortic vessels, carotid bifurcation, distal ICA, intracranial arteries, and
brain. Conversely, the main asset of duplex ultrasound is the haemo-
dynamic data provided by Doppler. Stenosis assessment is based pri-
marily on direct signs: ICA peak systolic velocity, ICA end-diastolic
velocity, and carotid ratio (Table 2).
In the case of severe stenosis (>80%) or ICA occlusion, indirect signs
can give additional information: altered intracranial blood flow (transcra-
nial Doppler) and/or reduced or reverse flow in the ophthalmic artery.42
Catheter angiography is no longer needed apart from during endo-
vascular procedures.
Carotid stenoses require the best medical treatment whether they
are symptomatic or asymptomatic. In symptomatic patients, studies
show the maximum benefit of carotid endarterectomy (CEA) is in
patients with NASCET 70–99% stenoses (number needed to treat =
6). The benefit was lower in patients with 50–69% NASCET stenoses
(number needed to treat = 13), and no benefit was found in patients
with NASCET 0–49% stenoses. Revascularization should preferably
be done within 14 days of symptom onset.44
Optimal medical treatment has considerably reduced the risk
of ischaemic stroke in patients with asymptomatic ICA stenoses,
and currently, there is sufficient evidence for a more conservative
approach in these individuals.4 Nevertheless, predicting how dan-
gerous an asymptomatic ICA stenosis is remains difficult. Some
clinical and imaging features are associated with an increased risk
of ischaemic stroke (Table 3). According to the European Society
of Cardiology guidelines,4 CEA should be considered in patients
with asymptomatic 60–99% ICA stenoses, life expectancy
>5 years, favourable anatomy, and >_1 feature suggesting higher
stroke risk on best medical treatment.
Ischaemic strokes can be caused, less frequently, by non-
atherosclerotic lesions: arteritis (giant cell or Takayasu arteritis), dissec-
tion (e.g. trauma, idiopathic, Marfan syndrome, fibromuscular dysplasia,
Ehlers-Danlos syndrome, carotid bulb diaphragm).
Figure 3 NASCET and ECST methods: A, B, are measured with
colour Doppler, B-flow, or eFlow; C is the normal lumen diameter
before development of the stenosis.42 ECST, European Carotid
Surgery Trialists; NASCET, North American Symptomatic Carotid
Endarterectomy Trial NASCET.
Figure 4 Area-reduction method for measuring internal carotid
artery stenoses.
.................................................................................................






ECST, European Carotid Surgery Trialists; NASCET, North American
Symptomatic Carotid Endarterectomy Trial.







aging/advance-article/doi/10.1093/ehjci/jeab008/6168685 by guest on 12 M
arch 2021
....................................................................................................................................................................................................................
Table 3 Clinical and imaging features associated with increased risk of ischaemic stroke in patients with asymptomat-
ic ICA stenosis4
Clinical features Contralateral TIA/stroke
Cerebral imaging Ipsilateral silent infarction
Ultrasound Stenosis progression (>20%)
Stenosis characteristics: large plaque, echolucent plaque, juxta-luminal hypoechogenic area
Vascularization of the plaque (contrast-enhanced echo)
Impaired cerebral vascular reserve (transcranial Doppler)




ICA, internal carotid artery; MRI, magnetic resonance imaging; TIA, transient ischaemic attack.
....................................................................................................................................................................................................................
Table 2 Combined criteria for grading ICA stenosis (according to von Reutern et al.43)
% stenosis 50% 60% 70% 80% 90%
PSV threshold 125 cm/s 230 cm/s
PSV average 210 cm/s 240 cm/s 330 cm/s 370 cm/s Variable
PSV post-stenotic >_50 cm/s <50 cm/s <30 cm/s
EDV in the stenosis <100 cm/s >100 cm/s
Carotid ratioa >_2 >_2 >4 >4
EDV, end-diastolic velocity; ICA, internal carotid artery; PSV, peak systolic velocity.
aICA PSV divided by common carotid artery PSV.
.........................................................................................................................................................................................................................
Recommendations for cardiovascular imaging tools45
TTE, TOE, CMR
TTE should be performed systematically before TOE for evaluation of the cardiovascular source of embolus.
Contrast TTE, using intravenous injection of agitated saline, should be performed systematically at baseline and after provocative manoeuvres (Valsalva man-
oeuvre, coughing, both).
General indications in search of cardiac or aortic sources of embolism
Contrast TTE is the initial imaging modality of choice for evaluation of the cardiac and aortic sources of embolus.
Contrast TOE should be done in selected patients for evaluation of the cardiovascular sources of embolus if no identified source is found on TTE.
Contrast TOE should be performed according to the clinical context, but emergent indications are limited (e.g. fever, prosthesis).
Contrast TOE should be performed rapidly (ideally within 48 h) in case of ischaemic stroke, peripheral embolism, or previous heart valve replacement (per-
cutaneous or surgical).
Contrast TOE is not indicated in ischaemic stroke patients with a previously identified source.
A comprehensive stroke CT protocol, including the intracranial and cervical arteries, aortic arch, cardiac chambers and walls, and coronary arteries, can be
proposed in trained centres as an alternative initial imaging modality for evaluation of the cardiac and aortic sources of embolus.
CMR could be proposed in unselected patients with cryptogenic stroke who have a non-diagnostic cardiac evaluation including contrast TOE.
Vascular imaging
Doppler ultrasound (first-line), CTA, and/or MR angiography are recommended for evaluating carotid stenoses.
When carotid stenting is being considered, it is recommended that any Doppler ultrasound study be followed by either MR or CTA to evaluate the aortic
arch, as well as the extra- and intracranial circulation.
When CEA is considered, it is recommended that Doppler ultrasound be corroborated by MR or CTA or repeat Doppler ultrasound performed by an
expert.
CEA, carotid endarterectomy; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; MR, magnetic resonance; TOE, trans-
oesophageal echocardiography; TTE, transthoracic echocardiography.























































Cardiac sources of cerebral
embolism
Major cardiac sources of cerebral
embolism
Major (as well as minor and unclear) sources of cerebral embolism
are detailed in Table 4.
Left atrial thrombus and risk factors
Left atrial thrombi
LAT and particularly LAAT are the primary sources of cerebral em-
bolism and are the most common sites for intracardiac thrombi.
They are primarily, but not exclusively, seen in patients with AF and
mitral stenosis.46 AF is the most frequent dysrhythmia and is closely
associated with advancing age. The stratification risk of thrombo-
embolic events in AF is currently based on clinical risk scores, mainly
CHADS2
47 (Congestive heart failure, Hypertension, Age >_75 years,
Diabetes mellitus, prior Stroke, TIA, or thromboembolism) and
CHA2DS2-VASc
48 [Congestive heart failure, Hypertension, Age
>_75 years, Diabetes mellitus, prior Stroke, TIA, or thromboembol-
ism, Vascular disease, Age 65–74 years, Sex category (female)]. The
risk of stroke for individuals in sinus rhythm increases along with left
atrial (LA) dimensions.49 LA/LAA thrombus is very infrequently
detected in the presence of sinus rhythm.46 LAT and LAAT are often
associated with spontaneous echocardiographic contrast (SEC),
defined as dynamic ‘smoke-like’ and slowly swirling echodensities in
the left atrium (LA) and/or LAA. TOE is the gold standard for the
diagnosis and exclusion of LAT and LAAT, and is a useful tool for em-
bolic risk stratification in AF. TOE allows the identification of risk fac-
tors for thromboembolism such as LV ejection fraction (LVEF)
<35%,50 complex aortic plaques, SEC in the LA/LA appendage
(LAA), and LAT/LAAT, LAA dysfunction as measured by emptying/
filling velocities <_20 cm/s on pulsed Doppler,50 and dynamic evalu-
ation of LA function by evaluation of LA global longitudinal strain.
Whereas TTE is recommended in all patients with AF to identify
the underlying causes of AF, TOE as a semi-invasive tool is not sys-
tematically needed. In a meta-analysis by Romero et al.,24 the mean
sensitivity and specificity of cardiac CT was, respectively, 96% and
92% compared with TOE. In a further subanalysis of seven mostly
prospective, single-centre studies in which delayed imaging CT was
performed, sensitivity and specificity further increased to 100% and
99%, respectively.
In addition to its non-invasive character, CT also offers a superior
visualization of the anatomy of the LAA.51
In a retrospective registry analysis of patients undergoing pulmon-
ary vein isolation, all thrombi detected by TOE were also found with
the use of delayed enhancement cardiac MRI.27
Rheumatic valve disease (mitral stenosis)
Rheumatic valve disease and mitral stenosis are still common in
developing countries. Patients with rheumatic mitral stenosis are at
increased risk for embolic events. Systemic embolization occurs in
10–20% of patients with mitral stenosis, with 75% of cases manifest-
ing as cerebral embolism.52–54 Various factors are related to an
increased risk for embolization, including age, AF, and LA enlarge-
ment.54–56 Embolic events can be the first clinical manifestation of the
disease and do not appear to be related to the severity of mitral
stenosis.52
Although AF appears to be a determining factor in the formation
of left intra-atrial thrombosis and is a major potential source of per-
ipheral arterial embolism in mitral stenosis, 8–20% of patients pre-
senting with mitral stenosis and systemic embolism are in sinus
rhythm.57,58 In these patients, not only the size and shape of the LA
but also the presence of SEC is significantly associated with a higher
risk of clot formation.58
Oral anticoagulant therapy is mandatory when AF complicates mi-
tral stenosis, regardless of its severity and CHA2DS2-VASc score. In
patients with mitral stenosis and sinus rhythm, those with larger LA
volume and the presence of SEC might also benefit from prophylactic
anticoagulation. Non-vitamin K antagonist oral anticoagulants are not
recommended in moderate-to-severe mitral stenosis due to the lack
of data.59
Atrial fibrillation
The most common cardioembolic sources of ischaemic stroke are
LAAT during AF; however, a thrombus can also rapidly appear just
after reduction of the arrhythmia, during the stunning period, despite
the absence of thrombus when the patient was in AF.60
AF affects 0.3–0.4% of adults,61 and the prevalence rises with age
to 10% in those >75 years.62 Specific recommendations about the
use of multimodality imaging in that field have been published by the
European Association of Cardiovascular Imaging (EACVI).60 The inci-
dence of ischaemic stroke in patients with AF reportedly ranged
from 1% in low-risk patients to 15% in high-risk patients, and silent
AF was detected in 26% of patients who had recently had a crypto-
genic stroke.61 The loss or reduction of LA and LAA contractility
.................................................................................................
Table 4 Major and minor/unclear sources of ischaemic
stroke
Major sources of stroke risk Minor or unclear sources
of stroke risk
Atrial fibrillation Mitral valve prolapse
Recent myocardial infarction Mitral annulus calcification
Previous myocardial infarction (LV
aneurysm)
Spontaneous echo contrast




Cardiac masses (except calcifications) Valvular strands





Rheumatic valve disease (mitral
stenosis)
Aortic arch atheromatous plaques Atrial septal pouch
Endocarditis Giant Lambl’s excrescences
Prosthetic valve (mechanical especially)
LV, left ventricular; PFO, patent foramen ovale.
































































































during AF causes a reduction of LAA emptying and an increase in
blood stasis, which is favoured by the chicken-wing (cul-de-sac) shape
and multilobate anatomical structure of the LAA.60,63 The risk of
thrombus formation can be conveniently estimated using the
CHA2DS2-VASc score,
48 which accurately predicts the risk of ischae-
mic stroke but only takes clinical variables into consideration.64,65 LA
and LAA anatomical and functional factors can, however, significantly
influence the risk of thrombosis. Recent studies that investigated LA
reservoir function have demonstrated the value of this echocardio-
graphic parameter for predicting the risk of ischaemic stroke.66–70
Accordingly, echocardiography has been proposed as a tool in the
management of patients with AF.60 TOE can accurately identify LAT
and LAAT, and provides fundamental information for the timing of
cardioversion in patients who have been in AF for >48 h, allowing im-
mediate cardioversion without the need for 3 weeks of anticoagula-
tion once the presence of LAT/LAAT has been excluded.60,71 In
addition, TOE can detect dense SEC, LAA contractility, and LAA
anatomy.51,72 CT angiography (CTA) is a reasonable alternative to
TOE when the primary aim is to exclude LAT and LAAT, and in
patients in whom the risks associated with TOE outweigh the bene-
fits (consider the delayed scan post-contrast).51,60
The recent literature strongly encourages the use of strain meas-
urement of LA reservoir function.66,73 Deformation of LA walls dur-
ing LV systole is associated with thromboembolic risk.70,74 The value
is independent of LA volume and may be a target for further treat-
ment strategies. The results from an ongoing large EACVI registry
will probably provide input for future guidelines.75
Imaging techniques are not currently used to estimate the risk of
AF, which can be silent and could be detected in patients who are
assessed by devices.76–78 Van Gelder et al.79 demonstrated that sub-
clinical AF lasting for >24 h is associated with an increased risk of is-
chaemic stroke or systemic embolism. In a study involving 1251
patients, 217 had SEC, 127 had LAT/LAAT, 241 had complex aortic
plaque, and 746 had none of these.80 The rates of ischaemic stroke/
systemic embolism were not significantly different among patients
with and without these echocardiographic findings when they are
properly treated with a non-vitamin K antagonist oral
anticoagulant.80
Atrial flutter
Atrial flutter is often associated with, or preceded by, AF; the annual
thromboembolic risk for patients with atrial flutter ranges from 1%
to 5%.81 The primary and secondary prevention methods are the
same as for AF.82–85
In a meta-analysis of 52 studies that assessed the relationship be-
tween atrial flutter and ischaemic stroke, Vadmann et al.86 showed
that observational studies reported an overall elevated stroke risk
(risk ratio 1.40, 95% CI 1.35–1.46) and mortality risk [hazard ratio
(HR) 1.9, 95% CI 1.2–3.1] over long-time follow-up compared with a
control group. Moreover, this study confirmed that clinical thrombo-
embolic events, LAT, and SEC are highly prevalent in patients with
atrial flutter.86
Left atrial/left atrial appendage spontaneous echocardiographic contrast
SEC refers to smoke-like echoes that can be visualized on echocardi-
ography when ultrasound is backscattered by red blood cell
aggregates.87 The severity of SEC is graded from 0 to 4 according to
the Fatkin classification,88 with the following criteria:
(1) Mild (minimal echogenicity located in the LAA or sparsely distrib-
uted in the main cavity of the LA; may be detectable only transiently
during the cardiac cycle; imperceptible at operating gain settings for
2D echocardiography analysis);
(2) Mild to moderate (more dense swirling pattern than grade 1, but
with similar distribution; detectable without increased gain settings);
(3) Moderate (dense swirling pattern in the LAA, generally associated
with somewhat lesser intensity in the main cavity, may fluctuate in
intensity but detectable constantly throughout the cardiac cycle);
and
(4) Severe (intense echodensity and very slow swirling patterns in the
LAA, usually with similar density in the main cavity).89
More recently, sludge (an early thrombotic stage) has been defined
in echocardiography as a dynamic, viscid, layered echodensity with-
out a discrete mass, visualized throughout the cardiac cycle.90
SEC has been associated with a higher rate of ischaemic stroke in
patients with AF (Supplementary data online, Table S3). Furthermore,
clinical outcomes in patients with ischaemic stroke and AF are poor
in the presence of coexisting SEC.91,92 TOE plays an important role
in detecting and defining the degree of SEC in the LA cavity.89,93,94
Sludge has been reported to be abolished with appropriate anticoa-
gulation, in contrast to SEC. Sludge is an independent predictor of
embolic events and all-cause death.63,90,93
Among patients with AF of different causes, greater than mild mi-
tral regurgitation was much less associated with LA SEC than mild or
lesser mitral regurgitation.95
Left atrial appendage dysfunction
Multimodality imaging of left atrial appendage and association with is-
chaemic stroke. The development of LA ablation procedures and
LAA occlusion devices for the treatment of AF has increased the
interest in LAA anatomy and function.96–98 The LAA is an embryonic
remnant of the primordial LA and is an important site of thrombus
formation in AF. Anatomically, the LAA is divided into three regions:
the ostium, the neck, and the lobar region. The LAA ostium is usually
oval, but can be round, triangular, or water-droplet shaped.99 A post-
mortem study100 reported that most people had two lobes (54%),
followed by three lobes (23%), one lobe (20%), and four lobes (3%).
In most cases, the tip of the LAA is directed antero-superiorly and
the LAA extends between the anterior and lateral walls of the LA.99
The LAA contains pectinate muscles, which have to be differentiated
from thrombi. With its complex morphology and function, the LAA
can be studied using TTE, 2D/3D TOE, CT, and MRI to improve
understanding of its association with ischaemic stroke. A 3D modality
is recommended to best assess the complex shape of this structure.
Two-dimensional transthoracic echocardiography. TTE imaging provides
partial evaluation of the LAA. Unusually LAAT can be visualized using
TTE. Some authors have reported a relationship between LAA dys-
function—measured by LAA wall velocity using TTE—and cerebro-
vascular events.101 In addition to LAA evaluation, TTE imaging is
essential for the evaluation of LAA risk of thrombus formation and
cardioembolic events. LV dysfunction is an echocardiographic risk






























































factor for LAAT, probably mediated by ventricular diastolic dysfunc-
tion and its effect on LA dynamics and pressure. Evaluation of diastol-
ic function may improve stroke prediction in patients with non-
valvular AF. E/e0 ratio and e0 velocity are associated with LAAT, inde-
pendent of CHA2DS2-VASc score.
102 LA volume and mechanical
dysfunction are closely associated with high risks of LAT and LAAT
formation, and increased LA volume increases the risk of first ischae-
mic stroke.103 LA global longitudinal strain—assessed using speckle-
tracking TTE—discriminates the presence of LAT or LAAT on TOE
in patients with acute ischaemic stroke.74
Transoesophageal echocardiography (2D initially and now, mainly 3D with
all capabilities related to the 3D acquisition). TOE is a mandatory com-
plement to TTE for the optimal evaluation of LAA anatomy and func-
tion. The LAA can be visualized using 2D TOE in the mid-
oesophageal view by rotating the imaging sector from 0 to 180 . For
LAAT detection—in comparison with surgical data—TOE has excel-
lent sensitivity (92%) and specificity (98%).104,105 Some years ago, be-
fore the dissemination of 3D TOE probes, some authors
demonstrated that contrast injection could enhance visualization of
the LAA and facilitate the exclusion of LAAT on TOE.72,106
One of the strengths of 2D TOE is the ability to perform Doppler
evaluation of the emptying and filling velocities of the LAA (Figure 5).
LAA blood-flow velocities are obtained using pulsed Doppler by
positioning the sample volume at the proximal third of the LAA cavity
after necessary gain and filter adjustments. LAA flow during sinus
rhythm is divided into several phases.107,108 After mitral valve open-
ing, the following can be successively measured: early positive diastol-
ic LAA emptying (the consequence of LV filling); early negative
diastolic LAA filling (the consequence of LA filling); late positive dia-
stolic LAA emptying (LAA contraction); early negative systolic LAA
filling (LAA elastic recoil); and systolic reflection waves. In AF, no
identifiable waves are individualized in the LAA, with a ‘saw tooth’
flow profile.
LAA dysfunction with alterations in LAA emptying and filling veloc-
ities <20 cm/s have been associated with an increased risk of throm-
bus formation within the LAA and a higher incidence of
thromboembolic events in patients in normal sinus rhythm.109,110
3D TOE is superior to 2D TOE for anatomical evaluation of the
LAA. 3D TOE has become ‘a must’. 3D TOE allows visualization of
the entire LAA and LAA orifice, their relation to the surrounding
structures (mitral valve and left upper pulmonary vein), and
evaluation of LAA volume, LAA ejection fraction, and LAA orifice
area.111–113 3D TOE has to be considered to differentiate thrombi
from artefacts or pectinate muscles within the LAA.112,113
In acute ischaemic stroke, LAA volume (analysed by real-time 3D
TOE) is larger in patients with versus those without paroxysmal
AF.114 Multivariable analysis revealed CHADS2 (P = 0.002), LVEF
(P = 0.01), degree of LA SEC (P = 0.02), LA volume (P = 0.02), and
number of LAA lobes (P < 0.001) to be independently associated
with thrombus formation. Most patients with LAA thrombus (32/34,
94.4%) had >_3 LAA lobes.115
Cardiac computed tomography and cardiac magnetic resonance imaging.
In cardiac CT, differentiation between thrombi and blood stasis is
possible with the analysis using delayed imaging.116–119 In a meta-
analysis of 753 patients with delayed imaging of the LAA, the mean
weighted sensitivity and specificity for the detection of LAAT was
100% and 99%, respectively, and the positive predictive value and
negative predictive were 92% and 100%, respectively.24
Using CT, a larger LAA orifice area is a significant risk factor for is-
chaemic stroke (adjusted odds ratio 6.16, 95% CI 2.67–14.18;
P < 0.001).120 Using MRI, ischaemic stroke risk has been reported to
be highest in patients with an LAA volume >34 cm3.121 A retrospect-
ive study reported an association between LAA morphology and pre-
vious thromboembolic events, using CT and MRI.122
LAA morphology has been classified into four types: chicken wing,
cauliflower, windsock, and cactus, based on cardiac CT. In a meta-
Figure 5 2D TOE: pulsed Doppler in the LAA during (left) sinus rhythm and (right) AF. (1) Early positive diastolic LAA emptying; (2) early negative
diastolic LAA filling; (3) late positive diastolic LAA emptying (just after the P-wave on the electrocardiogram); (4) early negative systolic LAA filling;
(5) systolic reflection waves. 2D, two-dimensional; AF, atrial fibrillation; LAA, left atrial appendage; TOE, transoesophageal echocardiography.




















analysis of eight studies, patients with chicken wing morphology were
less likely to have an embolic event compared with the other LAA
morphologies.123 LAA morphology by CT is an independent deter-
minant of LAA flow velocity by TOE, suggesting an association be-
tween LAA morphology (and number of lobes) and embolic
events.124 Delayed contrast CT has been shown to be almost as sen-
sitive as TOE for detection of LAAT.24–27
Using MRI, extensive fibrosis of the LA is a significant predictor of
TOE abnormalities (LAAT or SEC).125
Summary
Figure 6 summarizes the multimodality imaging of LAA thrombi and
Figure S1 the echocardiographic predictors of LAAT formation and is-
chaemic stroke. Supplementary data online, Tables S4 and S5
Figure 6 Multimodality imaging of LAA thrombi: (A) 2D TTE parasternal short-axis view depicting LAA thrombus in a patient with mitral stenosis;
(B) TOE illustration of the different grades of LA SEC (see Supplementary data online, Video S1A–D); (C) 2D TOE: pulsed Doppler in the LAA during
AF; (D) 3D TOE: analysis of the ostium of the LAA (upper left) and volume evaluation (upper right); example of LAA thrombus in a patient with mitral
stenosis (bottom) (see Supplementary data online, Video S2); (E) Cardiac CT, arterial phase on the left and delayed phase on the right (90 s after iod-
ine injection), two-chamber view on the top and axial view on the bottom, showing LAAT (courtesy of Gilles Soulat, MD, PhD). 2D, two-dimension-
al; 3D, three-dimensional; AF, atrial fibrillation; AO, aorta; CT, computed tomography; LA, left atrium; LAA, left atrial appendage; LAAT, left atrial
appendage thrombus; LASEC, left atrial spontaneous echocardiographic contrast; RA; right atrium; SEC, spontaneous echocardiographic contrast;
TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
































































































summarize studies that assessed the associations between: LAA anat-
omy/function and LAAT; diastolic function and LAAT; and LAA anat-
omy/function and LAA flow velocity (Supplementary data online,
Table S4)102,115,124; and LAA anatomy/function and ischaemic stroke
(Supplementary data online, Table S5).101,109,120,122,123
Atrial cardiomyopathy
Atrial cardiomyopathy is defined in the EACVI/European Heart
Rhythm Association expert consensus document60 as ‘any complex
of structural, architectural, contractile, or electrophysiological
changes affecting the atria with the potential to produce clinically
relevant manifestations’.126 This term implies adverse consequences
that can be independent of atrial arrhythmias.
The presence and type of cardiomyopathy are independent pre-
dictors of ischaemic stroke in patients with AF; however, atrial car-
diomyopathy may be an independent determinant of stroke risk. In
fact, frequent temporal discordance between AF episodes and stroke
leads to the concept that an underlying atrial cardiomyopathy may
cause thromboembolism even in the absence of AF.127
Atrial remodelling is caused by cardiovascular diseases or risk fac-
tors, including ageing-induced atrial remodelling, through fibrosis,
leading to LA/LAA mechanical and endothelial dysfunction (LA
strain), substrate for increased LA thrombogenicity though
Virchow’s triad, and thus increased risk of ischaemic stroke.128
Recently, Habibi et al.129 reported an inverse association between LA
reservoir function [measured as total LA ejection fraction, using MRI
in the Multi-Ethnic Study of Atherosclerosis (MESA) study] and the
risk of cerebrovascular events. This association was independent of
known cerebrovascular risk factors and AF.
The concept of a thrombogenic atrial cardiomyopathy remains
speculative, but the assessment of atrial structure (LA volume),
function (LA ejection fraction, LA strain), and fibrosis (cardiovascular
MR) may help improve stroke risk stratification independently from
the presence of AF.
Left ventricular thrombus and risk factors
Recent myocardial infarction
Ischaemic heart disease, notably acute anterior MI, is a major source
of LV thrombus (LVT) formation. Here, the combination of blood
stasis and an inflamed necrotic myocardium predispose to thrombus
formation. Several other cardiac conditions are also associated with
LVT formation, including dilated cardiomyopathy (DCM), stress-
induced cardiomyopathy, and severe LV systolic dysfunction (LVSD)
complicating valvular heart disease. The overall prevalence of LVT in
the general population is low. In a retrospective review of >80 000
medical records, the incidence of LVT was 7 per 10 000 patients.130
Of these cases, 80% were related to infarction while the rest were
due to DCM and stress-induced cardiomyopathy.130 LVTs have been
reported in 4–39% of patients with anterior wall MIs.131 The preva-
lence of LVT following an MI was 9.1% in recent study in which CMR
was systematically used.132
LVTs appear as echo-dense masses within the LV cavity, adjacent
to an abnormally contracting LV segment (akinetic and less frequently
hypokinetic) or an aneurysmal myocardium. The LVT appears to
have distinct margins between the LV wall and the LV cavity, a struc-
tural texture that is different from the LV myocardium, and a clear
thrombus–blood interface. The LVT is visible throughout the entire
cardiac cycle and in at least two modified views or transducer posi-
tions. The LVT shape is called ‘protuberant’ (intracavitary) when the
borders mainly protrude into the LV cavity. It may be pedunculated
or sessile. The LVT shape is termed ‘mural’ when the mass is flat and
parallel to the contiguous endocardial surface (concave borders).
The LVT is considered mobile when a segment of it moves independ-
ently of the adjacent endocardial motion.
Weinsaft et al.133 reported a specificity for TTE as high as 100% for
LVT detection. However, TTE has a lower sensitivity for detecting
LVT (21–33%) compared with late gadolinium enhancement CMR.
Sensitivity of TTE increases to 61% when contrast agents are used.
TTE performance for LVT detection may vary according to the clinic-
al indication of the echocardiograph.133 When echocardiograms
were performed for the well-defined clinical indication of LVT, TTE
sensitivity increased from 26% to 60% and TTE positive predictive
value increased from 21% to 75%.134
The diagnosis of LVT is facilitated by using a contrast echocardio-
gram, as the contrast fills the LV cavity and thus enhances the visibility
of endocardial border delineation. LVT appears on contrast images
as a dark linear or protruding structure, adjacent to akinetic (or hypo-
kinetic) myocardium, and is surrounded by opacified blood (which
appears bright) in the LV cavity. LVT identification is based on ana-
tomical appearance.
Rates of sensitivity and specificity of 88% and 96%, respectively, for
conventional echocardiography have been reported using contrast
echocardiography for the detection of LVT in a series of 392 patients
with anterior MI.135
MRI has a higher sensitivity and specificity for the detection of LV
thrombi compared with TTE and is considered the gold standard in
this setting.33 Delayed-enhancement cardiac MRI has been validated
.....................................................................................................
Recommendations on imaging techniques to evaluate LA/LAA
anatomy, geometry, and function in AF
LA/LAA SEC and sludge should be reported when a TOE is performed.
The degree of LA/LAA SEC is associated with the prognosis.
Repeated TOE is indicated to monitor resolution of LAT/LAAT after
anticoagulation in the case of AF/atrial flutter cardioversion and/or
ablation.
3D TOE (better than 2D) is recommended for the anatomical and func-
tional evaluation of the LAA and evaluation of LAAT.
CT and MRI are recommended for a more complete assessment of LAA
anatomy before/during procedures of ablation of atrial arrhythmias
and percutaneous LAA closure. LAA geometry is better defined with
CT scans.
CT may detect LAAT with similar sensitivity and specificity than TOE
when a delayed imaging is used.
2D, two-dimensional; 3D, three-dimensional; AF, atrial fibrillation; CT, computed
tomography; LA, left atrial; LAA, left atrial appendage; LAAT, left atrial appendage
thrombi; LV, left ventricular; MRI, magnetic resonance imaging; SEC, spontaneous
echocardiographic contrast; TOE, transoesophageal echocardiography; TTE,
transthoracic echocardiography.
































































































as a more sensitive method for detecting LVT compared with cine
MRI. Indeed, in this sequence, the thrombus is characterized by the
absence of contrast agent enhancement.136 Nevertheless, TTE is
most frequently used for the detection of LVT and may serve as an
initial screening test. In a large study of 361 patients who had surgical
or pathological validation, the sensitivity of cardiac MR was 88% and
the specificity was 99%.137
On cardiac CT, LVT has a significantly lower attenuation in com-
parison with a normally perfused myocardial wall.138 Currently, there
are few validated data on the role of cardiac CT in the detection of
LVT in comparison with TOE or MRI. Figure 7 illustrates examples of
LVT diagnosed using TTE and MRI.
Pathological evaluation may distinguish fresh thrombi (no organiza-
tion), organizing thrombi, and laminated chronic organized thrombi.
CMR characteristics enable distinction between acute and older
thrombi. An acute thrombus shows high signal intensity on T1- and
T2-weighted images, whereas an older thrombus has low signal inten-
sity in both T1 and T2 sequences and occasionally shows evidence of
calcification.139 Embolic risk increases with more mobile thrombi and
a greater number of thrombi. In a retrospective study, the overall
rate of post-treatment thromboembolism in patients on anticoagu-
lant treatment was about 17%.130 However, this rate can vary from
0% to 33%.140–147 Clinical or pathological endpoints at 6-month
follow-up (TIA, cerebrovascular accident, or pathology-verified
thrombus) seem to occur more frequently in patients with LVT
detected by delayed-enhancement CMR than with TTE (16.7% vs.
7.7%).134
Certain LVT characteristics are known predictors of embolism,
including LVT morphological variations over time in serial examina-
tions, protruding shape, and mobility.148
Acute phase of myocardial infarction. Subsequent to the Olmsted
County study,149 a meta-analysis150 reported a prevalence rate of
11.1 for ischaemic stroke per 1000 MIs in patients hospitalized for MI.
At 1 month, the rate rose to 12.2 per 1000 and was 21.4 after
1 year.150 Predictors of ischaemic stroke after MI include older age,
diabetes, arterial hypertension, previous ischaemic stroke, anterior
MI, previous MI, AF, heart failure, and race.
LVT is reported in 20% of cases when the coronary artery is not
reperfused, and can reach 40% in anterior MI and 60% in the event of
extensive MI involving the LV apex.151 MI location and severity of LV
dysfunction determine the embolic risk.152 Thus, the rate of embolic
events can reach 20% in patients with extensive anterior MI and
LVT.153
Within 4 weeks of an acute MI, 1–2.5% of patients will present
with ischaemic stroke, most often (in 50% of cases) within the first
week.154–156 The risk is particularly high (4–12%) when the Q-wave
MI affects the anterior wall and apex of the LV.157,158 These locations
promote the formation of a left intraventricular thrombus, which
generally arises in the 10 days following an MI. The risk of ischaemic
stroke in patients presenting with an anterior MI and a left intraven-
tricular thrombus is 12% in the month following the MI.158 This risk
seems to be higher if the thrombus is pedunculated and mobile. The
risk of systemic embolism decreases markedly in the subsequent
months in the absence of AF and heart failure, irrespective of the nat-
ural history of the LVT.158 The incidence of embolism is high when
the thrombus is forming (first 3 months), but then decreases.159
The presence of preclinical coronary artery disease in patients
with stroke seems to be highly prevalent160 and is a major cause of
death during follow-up.161
Investigation of stroke patients for asymptomatic coronary artery
disease (using coronary artery calcium score, CT coronary angiog-
raphy, iodine coronary angiography), remains debatable.162
Cardiomyopathy
Cardiac thrombi are major sources of risk for embolism.16 Blood sta-
sis, myocardial wall damage, and hypercoagulability are the three
main determinants of intracardiac thrombus formation.
Dilated cardiomyopathy. Dedicated recommendations have been pub-
lished by the EACVI.163 Irrespective of their cause, all DCM cases can
be complicated by an LVT whose formation is promoted by the de-
crease in ventricular contractility,164 dilatation of cardiac cham-
bers,165,166 and, in certain cases, the presence of endocardial
lesions.167 The incidence of LVT in DCM ranges from 11% to 44%.167
AF increases this embolic risk.168 In patients with non-ischaemic
DCM, the risk of embolic events and ischaemic stroke is similar to
that in patients with ischaemic cardiomyopathy.164 The incidence of
ischaemic stroke seems to be related to the degree of LVSD.169
Chagas disease is caused by the parasite Trypanosoma cruzi, and it is
the most common cause of DCM in South America. Chagas cardio-
myopathy has a particular high risk of thromboemboli. A risk score
has been developed from a prospective study of 1043 patients with
Chagas cardiomyopathy. The following risk factors are summed: age
>48 years (1 point), ST-T changes on electrocardiogram (1 point), LV
apical aneurysm (2 points), and any degree of LVSD (2 points).
Patients with 4–5 points have an annual incidence of ischaemic stroke
of 4.4% and no patient with a score of 0 had stroke.6
Hypertrophic and restrictive cardiomyopathies. Hypertrophic cardiomy-
opathy (HCM) is a genetically inherited condition with a large clinical
spectrum and a wide variety of consequences, particularly the risk of
sudden death, heart failure, and, to a lesser degree, ischaemic
stroke.170,171 The level of evidence in regard to the risk of cardiac
emboli is weak. Maron et al.172 compiled 900 patients in a registry, 51
of whom (prevalence rate 6%) presented with an ischaemic stroke or
other vascular event during a mean follow-up of 7 ± 7 years. The
registry also included 44 cases of cerebral infarction. The overall an-
nual incidence was 0.8%, increasing to 1.9% for patients aged
>60 years. Most events (72%) arose in patients aged >50 years, al-
though 28% of the patients were <50 years. The onset of an ischae-
mic stroke or peripheral embolic event was independently associated
with signs of congestive heart failure, increasing age, and AF (present
in 88% of patients) at the time of the initial evaluation. The cumulative
incidence of peripheral and cerebrovascular events in patients with
AF was higher among those who were not receiving anticoagulant
treatment vs. those taking vitamin K antagonists (31% vs. 18%;
P < 0.05).172 In addition, specific disease complications were more
common in association with large or medium compared with small
aneurysms, such as ischaemic stroke/LV apical thrombus (4 vs. 0).173
In a study that enrolled 593 patients with clinically diagnosed
HCM (mean age at diagnosis 51.0 ± 15.6 years; mean follow-up
10.7 ± 7.5 years), 68 (11.5%) experienced ischaemic stroke and em-
bolic events.174 Among the 431 patients without previously












..documented AF (39 with events and 392 without events), older age
at diagnosis and LA dimension >_48 mm were identified as independ-
ent determinants of an embolic event. The incidence of ischaemic
stroke and embolic events was about 1.0% per year.174 Rowin
et al.175 showed that there is evidence of apical aneurysm in 4.8% of
all patients with HCM. Of these 4.8%, 14% had apical LVT, which was
Figure 7 Multimodality evaluation of LVT. (A) 2D TTE four-chamber and two-chamber (B) of an apical LVT (arrow) in a patient with recent MI
(see Supplementary data online, Videos S3A and B). (B) 2D TTE four-chamber. LVT (white arrow) in a patient with non-ischaemic cardiomyopathy.
(C) Cardiac MRI: short-axis view with cine MRI on the left [SSFP sequence (balanced steady state free precession)] and late gadolinium enhancement
on the right in a patient 48 h after ST-segment elevation MI involving the left anterior descending artery. Both no-reflow (yellow arrows) and LVT
(red arrow) are present in the late gadolinium enhancement images (courtesy of Gilles Soulat, MD, PhD). 2D, two-dimensional; LA, left atrium; LVT,
left ventricular thrombus; MI, myocardial infarction; MRI, magnetic resonance imaging; RA, right atrium; RV, right ventricle; SSFP, steady-state free pre-
cession; TTE, transthoracic echocardiography.





























































associated with thromboembolic events in non-anticoagulated
patients. These findings emphasize the importance of CMR in HCM.
Moreover, in HCM patients with cardioembolic events, a dedicated
assessment for LV apical aneurysm is needed to guide management
(including contrast TTE, and possibly adding CT/MRI). Multimodality
imaging techniques are essential for the diagnosis, prognostic evalu-
ation, and management of patients with restrictive cardiomyop-
athy.176 In restrictive cardiomyopathy, patients with cardiac
amyloidosis, and particularly those with AL (amyloid light-chain) type
and AF, have a very high risk for thromboemboli. Amyloid infiltration
of the atria and atrial mechanical dysfunction predispose to atrial
thrombi. Intracardiac thrombi were present in 33% of explanted or
autopsied hearts of patients with amyloid cardiomyopathy in a case
series of 116 patients from the Mayo Clinic.177 Of the 63 thrombi
found in this autopsy study, only one was an LVT.177 Embolic risk in
restrictive cardiomyopathy is mediated by atrial dysfunction, and LVT
is uncommon.
Other cardiomyopathies. Isolated LV non-compaction is characterized
by trabeculations with deep intertrabecular recesses in which
thrombi may form. A retrospective study of 144 patients with LV
non-compaction found a prevalence of cardioembolic stroke of 10%.
The majority of patients had either AF or LVSD.178
Takotsubo or stress cardiomyopathy is a transient form of regional
LVSD, most commonly involving the mid and apical left ventricle.
Ventricular thrombus was present in 1.3% patients with takotsubo
cardiomyopathy in a registry of 1750 patients.179
Heart failure. Olsson et al.180 reported on a study in 7599 patients div-
ided on the basis of their baseline LVEF (<_40% or >40%) and moni-
tored for a mean of 37.7 months. Patients with AF and low LVEF had
the highest absolute risk of cardiovascular events. Patients with AF
and low ejection fraction had the highest absolute risk of adverse car-
diovascular outcomes (e.g. 45% with cardiovascular death or con-
gestive heart failure hospitalization) relative to those with low
ejection fraction and sinus rhythm (37% with an event), preserved
ejection fraction, and AF (34% with an event), or preserved ejection
fraction and sinus rhythm (21% with an event).180 AF at baseline
remained an independent predictor of all-cause death regardless of
baseline ejection fraction: preserved ejection fraction HR 1.37 (95%
CI 1.06–1.79) and low ejection fraction HR 1.22 (95% CI 1.04–1.43).
In a retrospective study, Doukky et al.181 showed that diastolic
function indices E/e0 and e0 were independently associated with
LAAT in non-valvular AF.
Heart failure is associated with increased risks of ischaemic stroke
and intracerebral haemorrhage at short- and long-term follow-up.182
The associations persist in patients without AF or flutter, across age
groups and sexes.182 Di Tullio et al.183 showed that among patients
with systolic heart failure and sinus rhythm, LVEF of <15% more than
doubled the risk of ischaemic stroke. In randomized clinical trials, the
overall rate of ischaemic stroke in patients with heart failure with pre-
served ejection fraction and patients without AF (1.0% per year184)
was similar to the rate reported in patients with heart failure with
reduced ejection fraction without AF (CORONA study, 1.2% per
year).185 The CORONA study did not show that LVEF was an inde-
pendent predictor of stroke risk; however, only patients with an
LVEF <_45% were included.185
Cardiac masses
Intracardiac tumours
Primary benign cardiac tumours, a rare condition with a post-
mortem incidence of 0.1–0.3%,186 may affect the endocardium, myo-
cardium, or epicardium. Three-quarters of primary cardiac tumours
are benign. Atrial myxomas are the most prevalent type among be-
nign tumours, whereas cardiac sarcomas are the most frequent type
among malignant ones.187
The clinical presentation of cardiac tumours depends on the histo-
logical type, morphology, and intra-cardiac location. Four different
clinical manifestations can be produced by a cardiac tumour: systemic
(e.g. fever, fatigue, weight loss), embolic, cardiac, and metastatic. The
evidence to build a strong recommendation is limited.
Myxoma. Cardiac myxomas are generally sporadic tumours of endo-
cardial origin and are typically located in the LA opposite the fossa
ovalis region. They can also be located atypically in other areas of the
LA, in the right atrium (RA), or in the ventricles. Mean age at diagnosis
is 50 years, with 90% of patients aged 30–60 years.188 ‘Carney syn-
drome’ is present in 10% of cases and is characterized by multiple
and recurrent familial myxomas affecting young patients, people with
endocrine disorders or with a spotty skin pigmentation.189
The macroscopic appearance of a myxoma may be polypoid, often
pedunculated or papillary, with villous extensions.190 Microscopically,
myxomas are formed by a myxoid substance. Intratumoural haemor-
rhage or calcifications are often present.
The clinical manifestations of a cardiac myxoma are represented
by systemic symptoms, secondary embolization, or intracardiac ob-
struction.191 Myxoma embolization occurs in up to 75% of
patients192 and is associated with high morbidity and mortality.
Owing to the tumour localization, systemic embolization (including
cerebral arteries with ischaemic stroke and retinal arteries with sec-
ondary visual loss) is frequent. The risk factors for embolic events are
irregular surface, atypical localization, and large tumour size.193
.....................................................................................................
Recommendations for identification and evaluation of LVT
TTE is recommended for the evaluation of patients with cardiac condi-
tions who are at risk of LVT formation (e.g. MI, cardiomyopathy, se-
vere LV systolic dysfunction, non-compaction and takotsubo
cardiomyopathies).
TOE is not indicated when looking for LVT.
Contrast echocardiography and 3D echocardiography have to be consid-
ered to better characterize LVT. According to local facilities, CMR
could be preferred for its sensitivity.
CMR has higher sensitivity for identification of LV thrombi and should be
used when TTE is of suboptimal quality or when the TTE is negative in
the setting of suspected apical thrombus.
Repeated TTE is indicated to monitor resolution of LVT after 4–6 weeks
of anticoagulation.
3D, three-dimensional; CMR, cardiac magnetic resonance; LV, left ventricular;
LVT, left ventricular thrombus; MI, myocardial infarction; MR, magnetic reson-
ance; TOE, transoesophageal echocardiography; TTE, transthoracic
echocardiography.






























































Imaging can provide important information for diagnosis and manage-
ment: localization, insertion, size, appearance, mobility, and features
of embolic risk.
The main imaging modality for myxoma diagnosis is TTE, whereas
TOE is often necessary for morphological details (e.g. localization of
the attachment point). On cardiac CT, myxomas appear as isodense
or slightly hypodense masses with weak enhancement after iodine
contrast injection. Therefore, the differential diagnosis with a throm-
bus may be difficult.194 On MRI, myxomas have a homogeneous
hyperintense signal intensity on T2-weighted images, an isointense as-
pect on T1-weighted images, low signal on early gadolinium enhance-
ment, and intense signal enhancement on late gadolinium
enhancement, often with a hypointense core due to haemorrhage.194
Gadolinium enhancement imaging is an important method for differ-
entiating myxomas and thrombi.195
Fibroelastomas. Papillary fibroelastomas are papillary lesions of
the endocardium, generally located on the surface of cardiac
valves (80–90%), making them the most common valve tu-
mour.196,197 The aortic valve is most frequently affected.198
Cardiac papillary fibroelastomas are benign tumours with an inci-
dence of 0.002–0.33% in autopsy series, with incidence increasing
with age.199 Fibroelastomas represent almost 10% of intracardiac
tumours.200 The typical macroscopic description for a papillary
fibroelastoma is a ‘sea anemone’ due to its round shape with digi-
tations.201 Microscopically, the tumour consists of connective tis-
sue lined by endothelium.
The clinical manifestation of these tumours is very variable, from
asymptomatic incidental discoveries during echocardiography to is-
chaemic stroke or even sudden cardiac death due to tumour embol-
ization.200 Tumour localization (aortic valve), mobility, and
dimensions are predictors of arterial embolization.
Echocardiography is the first-line imaging modality. The echocar-
diographic appearance of a papillary fibroelastoma is a pedunculated
free-moving mass with high-frequency oscillations during the cardiac
cycle, with variable dimensions from a few millimetres to a few centi-
metres (rarely >3 cm), attached to the middle portion of the cardiac
valves but without any valvular destruction (enclosure is exceptional
and, although possible, regurgitation is minimal).198,202 On cardiac
MRI, the tumour might be not easily visualized due to its small size
and high mobility, but may be described as a hypointense mobile
mass on cine images.195
The differential diagnosis of the tumour includes valvular calcifica-
tions, thrombi, vegetations (generally associated with valvular
destructions), strands, and Lambl’s excrescences (generally arising
from the coaptation line). Figure 8 illustrates the use of multimodality
imaging in the diagnosis of cardiac masses.
Figure 8 Multimodality evaluation of cardiac masses. Myxoma
(left): same patient with LA myxoma: 2D TTE after (A) Sonovue
perfusion; (B) 3D TOE; and (C) cardiac CT (see Supplementary data
online, Video S4A and B, Videos S5–S7). Fibroelastoma (right): (A) 2D
TOE 120; (B) 3D TOE live 3D; and (C) cardiac CT: aortic fibroelas-
toma on the non-coronary cusp (white arrow) (see Supplementary
data online, Video S8Aand B) 3D. 2D, two-dimensional; 3D,
three-dimensional; Ao, thoracic aorta; AV, aortic valve; CT, com-
puted tomography; LA, left atrium; LAA, left atrial appendage; LV,
left ventricle; MV, mitral valve.
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Recommendations for evaluation of cardiac masses
The presence of a tumour may lead to a rapid surgical decision and this
decision should not be delayed by performing a useless diagnostic
examination. However, when making the decision on whether or not
to operate, a multimodality approach is often requested. Cardiac CT
and CMR are often considered in addition to echocardiographic
exams. A PET scan may also be valuable when a metastasis or primary
cardiac tumour is sought.
TOE (with 3D capabilities if possible) is recommended in addition to TTE
in evaluating cardiac tumours (e.g. myxoma, papillary fibroelastoma).
Contrast echocardiography or 3D echocardiography is recommended to
better characterize cardiac masses (atria > ventricles).
CT can be a helpful complementary tool to differentiate a myxoma from
a thrombus in cases in which TTE/TOE is inconclusive.
CMR imaging is considered as the modality of choice for evaluating car-
diac tumours.
3D, three-dimensional; CMR, cardiac magnetic resonance; CT, computed tomog-
raphy; PET, positron emission tomography; TOE, transoesophageal echocardiog-
raphy; TTE, transthoracic echocardiography.

























Infective endocarditis. Cerebral emboli are a frequent complication of
infective endocarditis and are related to the migration of infected
valvular vegetations in the cerebral arteries.203 These emboli occur in
15–30% of patients with infective endocarditis, can arise at any time
during the disease (before and during treatment), and are associated
with a worse prognosis.204–207
Echocardiography plays a major role in the assessment of embolic
risk in patients with infective endocarditis.203,208 The 2015 European
Society of Cardiology guidelines for the management of infective
endocarditis recommend that both TTE and TOE are performed in
patients with suspected or definite infective endocarditis.204 In a
meta-analysis of 16 observational studies, the diagnostic properties of
TTE for detecting infective endocarditis findings was compared with
those of TOE. For detecting vegetations, TTE had a sensitivity of 61%
and a specificity of 94%, and thus had the potential to miss many vege-
tations detected on TOE.209
Several factors have been associated with an increased risk of cere-
bral embolism.204,210,211 Among them, the size and mobility of the
vegetations are the most potent independent predictors of a new
embolic event211,212 (Supplementary data online, Table S6). Patients
with vegetations >10 mm are at higher risk of embolism and this risk
is even greater in patients with very large (>15 mm) and mobile vege-
tations, especially in staphylococcal infective endocarditis.208 An ob-
servational study213 found that the risk of neurological complications
was even higher in patients with very large (>30 mm) vegetations. In
a study of 847 patients with infective endocarditis, the 6-month inci-
dence of new embolism was 8.5%. Six factors (age, diabetes, AF, pre-
vious embolism, vegetation length, and Staphylococcus aureus
infection) were associated with an increased embolic risk and were
used to create an ‘embolic risk calculator’.211
The risk of embolism is particularly high during the first days
after the initiation of antibiotic therapy and decreases after
2 weeks,207 although some risk persists indefinitely while vegeta-
tions remain present, particularly for very large vegetations.213 For
this reason, the benefit of surgery to prevent embolization will be
greatest during the first week of antibiotic therapy, when the em-
bolic rate is highest.204
In addition to echocardiography, other imaging techniques
should be used for the assessment of patients with neurological
complications of infective endocarditis (Figure 9). These include
18F-fluorodeoxyglucose positron emission tomography (PET) CT,
which is particularly useful for the diagnosis of prosthetic valve in-
fective endocarditis,204,214,215 and cerebral imaging, which is man-
datory in patients with suspected or definite neurological
complications of infective endocarditis. This may include CT scan-
ning, with or without contrast, and/or MRI, depending on the
neurological status of the patient.204
In a meta-analysis of 20 studies (including 496 patients) with pros-
thetic valve infective endocarditis, TTE, TOE, and multidetector CT
plus TOE had a pooled sensitivity/specificity for vegetations of 29/
100%, 82/95%, and 88/94%, respectively. Although multidetector CT
data are limited, this review showed that multidetector CT in add-
ition to TOE may improve sensitivity in detecting life-threatening
periannular complications.216
Marantic vegetations. Non-bacterial thrombotic endocarditis
Non-bacterial thrombotic endocarditis (NBTE) is a form of non-
infectious endocarditis that most commonly affects patients with
advanced cancer (known as marantic endocarditis) and systemic
lupus erythematosus (known as Libman–Sacks endocarditis), but also
other chronic diseases.217–219 In these conditions, endothelial damage
and a hypercoagulable state concur to form sterile vegetations com-
posed of bland fibrin–platelet thrombi. These lesions can affect both
undamaged and damaged cardiac valves, as well as the chordae tendi-
neae or the endocardium. They are classically found in mitral and
Figure 9 Multimodality evaluation of infective endocarditis. (A)
2D TOE 120 and (B) 3D TOE zoom 3D: mitral posterior valve
vegetation in an active endocarditis (white arrow) complicated with
ruptured chordae tendineae; (C) 18F-FDG PET/CT images show
infected prosthetic aortic valve (see Supplementary data online,
Video S9). Ao, thoracic aorta; AV, aortic valve; CT, computed tom-
ography; FDG, fluorodeoxyglucose; LA, left atrium; LAA, left atrial
appendage; LV, left ventricle; MV, mitral valve; PET, positron emis-
sion tomography.






































































aortic valves along valvular coaptation lines and are usually small,
broad based, and irregularly shaped.220 In comparison to the lesions
in infective endocarditis, the weak inflammatory reaction at the site
of attachment renders NBTE vegetations more friable and prone to
systemic embolization, although they are less destructive and rarely
cause a significant degree of valvular dysfunction.221
The typical clinical presentation of NBTE is systemic embolization.
The incidence of cerebral ischaemia is higher in NBTE than in infect-
ive endocarditis (33% vs. 19%).222,223 Patients with NBTE tend to
have evidence of multiple, widely distributed brain infarcts on
diffusion-weighted MRI, whereas single lesions or focal infarcts are
more characteristic of infective endocarditis.224
The diagnosis of NBTE can be challenging and relies on strong clin-
ical suspicion. Laboratory studies and imaging techniques play a de-
cisive role in confirming a predisposing disease, establishing the
presence of valvular vegetations using echocardiography, and ruling
out infective endocarditis. TOE should be ordered when there is a
high suspicion of NBTE. TOE has a higher sensitivity and specificity
than TTE for the detection of NBTE; it should be considered either
as a complement to a non-diagnostic TTE or as the initial test in
patients with suspected cardioembolism, moderate or worse valve
dysfunction, or superimposed infective endocarditis.225,226
When an early TOE examination is performed, the prognosis of
NBTE is improved.227 A prospective study that compared paired 3D
TOE with 2D TOE in 29 patients with systemic lupus erythematosus
and manifestations of cerebrovascular disease demonstrated that al-
though 2D TOE has high diagnostic value for the detection of
Libman–Sacks vegetations, 3D TOE provides clinically relevant add-
itional information that complements 2D TOE for the detection,
characterization, and clinical correlations of Libman–Sacks endocar-
ditis.228 Following embolization, small remnants (<_3 mm) on affected
valves may result in false negative echocardiography results.204
Aortic arch atheromatous plaques
Imaging of the aorta is essential in the evaluation of ischaemic stroke
and peripheral embolization. Atherosclerotic plaque is the most
common source of embolism originating from the aorta
(Supplementary data online, Tables S7 and S8).229–234 In rare instan-
ces, embolism can arise from mobile thrombi235,236 or aortic
tumours.237 Atherosclerotic plaques are a manifestation of general
atherosclerosis and are associated with known atherosclerosis risk
factors such as hypertension, diabetes mellitus, advanced age, hyper-
cholesterolaemia, inflammation, and tobacco smoking.238,239
Atherosclerotic plaques in the aorta may cause either thrombotic
(thromboembolic) or atherosclerotic (cholesterol crystal) emboli.240
Thromboemboli are usually large and commonly occlude medium-
to-large arteries, causing ischaemic stroke, TIA, renal infarct, and per-
ipheral thromboembolism. By contrast, cholesterol crystal emboli
tend to occlude small arteries and arterioles and may cause ‘blue-toe’
syndrome, renal insufficiency, or mesenteric ischaemia. This athe-
roembolic syndrome can arise spontaneously,241 after the aorta is
instrumented during angiography or arterial catheterization,242,243 or
after heart surgery involving clamping of the aorta.244 Finally, mobile
thrombi of the aorta without diffuse atherosclerosis mostly located
at the aortic arch have been reported since the introduction of TOE
imaging for patients with cerebral or peripheral emboli. Clots floating
in the aorta frequently become embedded in atherosclerotic plaque
and carry a high embolic risk.236
The detection, characterization, and quantification of aortic pla-
ques can be accomplished by TOE, CT, or MRI. Several classifications
have been proposed to quantify severity of aortic atherosclerosis.
However, based on the results of most studies, atherosclerosis se-
verity is considered mild when intimal thickening (focal or diffuse) is
2–3 mm (grade I), moderate when the atheroma is <4 mm (grade II),
severe when the atheroma is >_4 mm (grade III), and complex when
any grade has associated mobile or ulcerated components (grade
IV).245,246
TOE provides higher resolution images than TTE for diagnosing
aortic atheroma. TOE characterizes the plaque by measuring plaque
thickness, ulceration, calcification, and superimposed mobile thrombi,
thereby determining the embolic potential of each plaque.
Compared with 2D TOE, 3D TOE provides superior visualization of
the number, morphology, volume, and spatial extent of aortic
......................................................................................................
Recommendations for evaluation of valvular vegetations
TTE is recommended as the first-line imaging modality in suspected in-
fective endocarditis.
TOE is recommended in patients with a high clinical suspicion of infective
endocarditis and a normal TTE, and when a prosthetic heart valve or
an intracardiac device is present.
TOE should be considered in the majority patients with suspected infect-
ive endocarditis, even in cases with positive TTE findings.
Repeat TTE/TOE within 5–7 days is recommended in case of initially
negative examination when clinical suspicion of infective endocarditis
remains high.
Additional imaging techniques (cardiac CT, PET/CT) that allow the diag-
nosis of embolic events and cardiac involvement should be performed
when TTE/TOE findings are negative or doubtful.
18F-fluorodeoxyglucose PET/CT is predictive of major cardiac events in
prosthetic valve endocarditis and new embolic events within the first
year following infective endocarditis.
TOE is recommended in case of systemic lupus erythematosus with or
without primary antiphospholipid antibody syndrome and ischaemic





Recommendations for evaluation of valvular vegetations
TTE is indicated in patients with cancer (e.g. lymphoma, carcinoma of the
gastrointestinal tract, and carcinoma of the lung) who have an ischae-
mic stroke or arterial embolism to document marantic vegetations.
TOE should be used in the characterization of valvular masses (differen-
tial diagnosis based on clinical and biological arguments).
CT, computed tomography; PET, positron emission tomography; MRI, magnetic
resonance imaging; TIA, transient ischaemic attack; TOE, transoesophageal echo-
cardiography TTE, transthoracic echocardiography.
































































































atheromas.247 Assuming the intrinsic limitation of suprasternal TTE,
this approach may be helpful for the preliminary screening of athero-
sclerotic plaques in the aortic arch. In one study, adequate transcuta-
neous image quality could be achieved in 84% of cases.248 This
approach may help to identify subjects at higher risk of subclinical
cerebrovascular disease.249 However, the low negative predictive
value of TTE does not allow aortic plaques to be ruled out or a com-
plex lesion to be correctly established.
The prevalence of aortic atheromas on TOE varies depending on
the population studied. In a community study,250 aortic atheromas
were present in 51% of randomly selected residents aged >_45 years,
with a greater prevalence in the descending aorta. Complex athero-
mas were present in 7.6%. In patients with known significant carotid
artery disease, the prevalence of aortic atheromas was 38%, and 92%
in those with significant coronary artery disease.
Aortic plaques with a complex lesion are a risk factor for recurrent
ischaemic stroke, silent brain infarction, and peripheral thrombo-
embolic events in patients with ischaemic stroke229,230 or TIA.231
This association has been described for proximal aortic plaques, par-
ticularly in the aortic arch232–234; however, no clear association exists
between the presence of descending aortic plaques and thrombo-
embolic events. Complex and severe atheromas of the ascending
aorta and aortic arch are associated with cerebral and peripheral em-
bolic complications.229,239 A meta-analysis251 has identified an
increased risk of cerebral infarction in patients with a plaque >_4 mm
in thickness, regardless of whether the two principal risk factors for
cerebral infarction in older adults (i.e. carotid stenosis and AF) were
also present. In addition to the presence of a plaque >_4 mm, the risk
of recurrent cerebral infarction is also higher in patients with ulcer-
ated, uncalcified plaques, and plaques with mobile elements.234,246
Attention has been drawn to some of the factors involved in aortic
thrombosis,252 such as hypercoagulability253 and high homocyst-
eine238 or ultra-sensitive C-reactive protein levels, independently of
other atherosclerotic risk factors.254
Few studies have focused specifically on the relationship between
atheroma and peripheral artery embolism outside the cerebrovascu-
lar region.255 However, TOE is indicated for the diagnosis of complex
atheroma or the presence of a large mobile thrombus of the aorta,
an infrequent cause of systemic emboli, which appears to be a com-
plication of atherosclerosis, but is not always extensive or severe.
Multidetector CTA of the aorta can also be used to detect aortic
atheromas. Its sensitivity, specificity, and overall accuracy for identify-
ing a severe aortic atheroma are similar to those of TOE, the refer-
ence method.256–258 Calcified plaque appears as a light, high-
attenuation signal, whereas lipid-rich or fibrous plaque appears as
hypo-attenuated dark signals within the vessel wall. In a retrospective
study, CTA had a high negative predictive value for aortic arch dis-
ease atheromas; however, sensitivity for detecting grade 1–4 athero-
mas was 53%.259 Benyounes et al.260 observed that agreement
between CTA and TOE is poor (61%) and that CTA lacks sensitivity
but had high specificity (93%) for detecting aortic arch atheromas.
Nevertheless, CTA has improved and can be reasonably considered
in routine clinical practice.
MRI provides information on plaque characteristics.261,262
However, MRI has limited utility for assessing mobile thrombi that
are often superimposed on plaques. Moreover, its spatial resolution
is inferior to that of CT. Compared with TOE, MRI overestimates
plaque thickness and consequently classifies more patients as at high
risk (>_4 mm plaque thickness).263 3D multicontrast MRI vessel wall
imaging is capable of characterizing at-risk atherosclerotic plaques in
the thoracic aorta.264 A recent study265 using a 3D multicontrast
protocol was tailored to characterize aortic plaque. The CMR
sequences showed high intra- and interobserver agreement regarding
image quality grading of the 3D sequences and assessment of four-
dimensional flow path lines. A high intra- and inter-rater agreement
of plaque classification evaluation according to American Heart
Association definitions.266
Figure 10 illustrates the use of multimodality imaging in the diagno-
sis of aortic arch atheromatous plaques.
Prosthetic cardiac valves (e.g. mechanical, biological,
clips)
Intracardiac devices and prosthetic valves represent a major source
of embolism. The presence of an intracardiac material in the setting
of an embolic event raises a high level of suspicion of a cardioembolic
source. A TOE is, in most cases, indicated within 48 h.
Two complications of prosthetic valve replacement must be sus-
pected when an embolic event occurs in a patient with a valve: pros-
thetic valve infective endocarditis (see section Infective endocarditis)
and prosthetic thrombosis. Prosthetic thrombosis is one of the most
severe complications of mechanical heart valves, although it has been
less frequently observed in other types of valve substitute. Particular
attention should be taken to the bioprosthesis, and especially to
transcatheter aortic valves.267 Situations at risk include the early post-
operative period, interruption of anticoagulant therapy, and preg-
nancy.267–269 Both TTE and TOE must be performed in suspected
prosthetic valve thrombosis as soon as possible:
• In severely obstructive thrombosis, TTE is the first-line examin-
ation and may provide evidence of an abnormal transprosthetic
colour flow jet, an elevated Doppler transprosthetic gradient, and
a reduced effective orifice area.
• A high transvalvular gradient is of great value for the diagnosis of
prosthetic thrombosis, especially when comparison with a refer-
ence value is available.
• Although direct evidence of valve thrombus may be obtained by
TTE, TOE is the method of choice to diagnose the main signs of
prosthetic thrombosis (restricted leaflet or disc motion, abnormal
central regurgitation, loss of physiological regurgitant jets in mech-
anical valves, and direct visualization of thrombus or pannus
formation).
• Cinefluoroscopy may also be useful assess leaflet motion of mech-
anical prostheses.
TOE is very helpful for assessing the extent of thrombus forma-
tion. Cardiac CT could be also considered. Recent evidence from ex-
pert teams demonstrates the great value of cardiac CT for identifying
thrombi that are not easily seen on echocardiography.270,271
The risk of embolism and complications in prosthetic thrombosis
is related to the size of the thrombus, with a large thrombus (>_0.8
cm2) being a major risk factor for complications of thrombolytic
treatment.272 Thus, TOE may help in the choice between surgery
and anticoagulant or thrombolytic therapy. TTE and TOE must also
be used for the follow-up of patients with prosthetic thrombosis after
initiation of specific therapy.273
















Diagnosis of partial prosthetic thrombosis is difficult, especially
when obstruction is mild or absent. TTE is of limited value in this set-
ting and TOE is the method of choice for the diagnosis of small pros-
thetic thrombosis. However, the diagnosis of prosthetic thrombosis,
even with TOE, suffers from some limitations. First, small abnormal
echoes around the prosthesis may also be observed in prosthetic
endocarditis, and it may be difficult to differentiate thrombus forma-
tion from vegetation. Moreover, examination of aortic prostheses is
Figure 10 Multimodality evaluation of aortic arch atheromatous plaque: TOE (left) and CTA and angio MRI (right). (A) 3D TOE Xplane showing
complex atheroma (>_4 mm in thickness and/or mobile components) of the ascending thoracic aorta with mobile components; (B) 3D live recon-
struction of complex atheroma of the ascending thoracic aorta; (C) CTA and (D) angio MRI showing atherosclerotic arch plaques >4 mm (courtesy
of Gilles Soulat, MD, PhD) (see Supplementary date online, Videos S10 and S11).
........................................................................................................................................................................................................................
Recommendations for evaluation of aortic arch atheromatous plaques
TOE is the reference echocardiographic method for the evaluation of thoracic aortic atherosclerosis location (descending, arch, ascending aorta) and sever-
ity (complex thoracic aortic plaques).234
TOE is the reference echocardiographic method for the description of complex thoracic aortic plaques (plaque thickness, ulceration, mobile elements sug-
gesting thrombus).
TOE can characterize aortic plaques as a surrogate marker of ischaemic stroke risk, irrespective of AF or carotid stenosis.
TTE (suprasternal window when available) can be used to identify aortic arch atheromas.
CT is competitive with TOE in aortic plaque (ascending and arch thoracic aorta) characterization.
MRI can be proposed in aortic wall and atherosclerotic plaque characterization.
AF, atrial fibrillation; CT, computed tomography; MRI, magnetic resonance imaging; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.




























































































..often difficult when a mitral prosthesis is also present, owing to at-
tenuation of the ultrasound beam. Cardiac CT should be considered
after clear agreement about the setting required to get valuable
results from the CT acquisitions.270




Atrial septal aneurysm (ASA) is defined as excursion of septal tissue
(typically the fossa ovalis) >10 mm from the plane of the atrial septum
into the RA or LA, or a combined total excursion right and left of
15 mm.274 Excursion of the atrial septum can be documented by 2D
imaging as well as by M-mode when the cursor can be aligned per-
pendicular to the plane of the interatrial septum. This can be done in
the subcostal four-chamber views by TTE or in the bicaval views by
TOE. The incidence of ASA in the general population, as estimated
by TTE, is considered to be only 0.23%,275 rising to 4.6% in TOE stud-
ies.22 The link between ASA and PFO is well established, with ap-
proximately 60% of patients presenting with ASA plus PFO.275 ASA
has also been associated with multiple septal fenestrations, and this
should be evaluated carefully by colour Doppler.276–278 TOE is a
more sensitive method than TTE for evaluating ASA. The presence
and extent of an ASA is a factor in device selection for PFO closure.
A relatively large device can be chosen to encompass and stabilize
the atrial septum or a smaller and softer device for better conform-
ation with the ASA.
The link between ASA and systemic embolism was initially
described from isolated cases.279 In one series,280 the incidence of
ASA was estimated to be 2.2% in the general population, signifi-
cantly lower than the 7.2% incidence in patients undergoing TOE
after an ischaemic stroke (P = 0.002). The embolic mechanisms
proposed included a thrombus in the ASA, a paradoxical embol-
ism from a venous thrombus through a PFO or coexisting parox-
ysmal AF.281
Patent foramen ovale
PFO is a flap-like opening between the septum primum and septum
secundum at the fossa ovalis. During foetal life, the foramen ovale
plays a physiological role, with the purpose of directing most oxygen-
ated placental blood from the RA to the LA, avoiding the pulmonary
bed. A PFO is the result of the failure of the septum primum and sep-
tum secundum to fuse postpartum. The reported prevalence of PFO
in the general population is 25%, increasing to over 50% in patients
with cryptogenic stroke.275,282 Paradoxical embolism occurs when
there is embolic transit from the systemic venous circulation to the
systemic arterial circulation through a right-to-left shunt, such as a
PFO or atrial septal defect. PFO refers to when right-to-left shunting
of blood has been demonstrated by saline contrast injection without
a true deficiency of the interatrial septum. Typically, the PFO is closed
due to the gradient between the LA and RA, and no left-to-right
shunting is seen. Under certain haemodynamic conditions, such as
elevated right atrial (RA) pressure due to acute or chronic pulmonary
hypertension, cough, or with a Valsalva manoeuvre, a right-to-left
shunt can be seen.
The presence of PFO is presumed when agitated saline contrast is
observed in the LA within three cardiac cycles after complete opacifi-
cation of the RA.283,284 Injections should be given at rest and with
certain provocative manoeuvres such as cough and the Valsalva man-
oeuvre to increase RA pressure. Deviation of the interatrial septum
to the LA side confirms elevated RA pressure. If agitated saline con-
trast is noted after five cardiac cycles, pulmonary arteriovenous mal-
formations must be considered.285,286 Elevated LA pressure from LV
failure or mitral valvular disease can prevent right-to-left shunting, be-
cause higher RA pressure is required to overcome the elevated LA
pressure. In a study comparing patients with or without left heart dis-
ease, the detection of PFO was 5% in patients with left heart disease
and 29% in those without left heart disease.287
TTE, TOE, and transcranial Doppler are useful for the diagnosis of
PFO16,284 (Supplementary data online, Table S9). Transcranial
Doppler records high-intensity transient signals, representing micro-
bubbles passing through the middle cerebral artery. TTE is the pri-
mary method reported to characterize the presence of right-to-left
shunting through a PFO and remains the most commonly used
screening test due to its non-invasiveness and wide availability. The
accuracy of TTE vs. TOE as the reference has been evaluated in a
meta-analysis, which included 13 studies with 1436 patients.288,289
The weighted mean sensitivity and specificity for TTE were 46% and
99%, respectively. Using different contrast agents, different micro-
bubble cut-offs for a positive TTE/TOE, and different cardiac cycle
cut-offs for a positive TTE/TOE, did not affect the accuracy of TTE. In
a population of patients with cryptogenic stroke, TOE had a sensitiv-
ity of 89% and a specificity of 91% for the diagnosis of PFO. The low
negative likelihood ratio of TOE suggests that it is a proficient test of
exclusion for PFO.290
In a systematic review of all prospective studies that assessed the
accuracy of TOE for the detection of PFO using confirmation by aut-
opsy, cardiac surgery, and/or catheterization as the reference, only
four studies met the inclusion criteria.290 Among 164 patients, TOE
had a weighted sensitivity of 89% and a specificity of 91% to detect
PFO.290
.....................................................................................................
Recommendations for prosthetic heart valves
TTE must be performed within the 48 first hours in patients with a pros-
thetic valve and an embolic event.
TOE must be performed in patients with a prosthetic valve and an em-
bolic event, even if the results of TTE are negative.
TOE plays an important role in guiding the therapeutic strategy in pros-
thetic thrombosis, the presence of a large thrombus favouring surgery.
Cinefluoroscopy should not be forgotten in case of a mechanical pros-
thesis, and cardiac CT should be considered.
Repeated TTE/TOE is recommended for follow-up after thrombolytic
therapy or anticoagulant therapy of a prosthetic valve thrombosis.
CT, computed tomography; TOE, transoesophageal echocardiography; TTE,
transthoracic echocardiography.












..TTE is recommended first and should be performed as its sensitiv-
ity is important and it is easier to perform the Valsalva manoeuvres
during a TTE. TOE is recommended in addition, but could be less
sensitive according the condition of the examination.290–293
Transcranial Doppler is a viable alternative to contrast TTE for
screening, with higher sensitivity than TTE, but with the disadvantage
of being unable to identify associated lesions, such as ASA, and failure
to distinguish pulmonary from cardiac sources of shunting.294
A meta-analysis compared transcranial Doppler with TOE as the
reference; both tests were performed with a contrast agent and a
manoeuvre to provoke right-to-left shunt.288 A total of 27 studies
(29 comparisons) with 1968 patients (mean age 47.8± 5.7 years; 51%
men) fulfilled the inclusion criteria. The weighted mean sensitivity and
specificity for transcranial Doppler were 97% and 93%,
respectively.288
A simultaneous study of TTE, TOE, and transcranial Doppler
showed TTE to be more sensitive than TOE for the diagnosis of
PFO.295 TOE returned a false negative result in 10% of patients, and
tended to underestimate the severity of right-to-left shunt.
Transcranial Doppler performed simultaneously with TTE and with
TOE showed that these false negatives were not due to the imaging
technique used itself, because transcranial Doppler performed during
TOE also yielded a similar number of false negatives, perhaps related
to sedation and lower quality of the Valsalva manoeuvre.295
Cardiac CT has been evaluated in 152 patients after ischaemic
stroke and showed a sensitivity of 73%, specificity of 98%, positive
predictive value of 91%, and negative predictive value of 94.7% for
the diagnosis of PFO. CT had a lower sensitivity than TOE in detect-
ing PFO, because PFO requires a provocative manoeuvre diagnosis,
which is impossible to do during CT.29 CT may be of limited use for
detecting cardioembolic sources in younger patients with stroke, as
the incidence of PFO or ASA is higher in younger patients with stroke
or those with cryptogenic stroke.37
Several studies have evaluated PFO as a predictive factor of recur-
rent ischaemic stroke in patients with cryptogenic stroke.285,296–301 A
strong association between PFO and ischaemic stroke has been
observed in patients of all ages.282,302 However, not all studies sup-
port the association between cryptogenic stroke and PFO.299,302,303
Despite circumstantial evidence, prospective studies have failed to
demonstrate causality between recurrent ischaemic stroke, presence
of PFO or ASA, or right-to-left shunt size.304–307 Similarly, contro-
versy exists in the management of these patients. A meta-analysis has
shown that among medically treated patients with ischaemic stroke/
TIA, those with PFO did not have a higher risk of recurrent cerebro-
vascular ischaemia than those without PFO.308 No relationship be-
tween the degree of right-to-left shunt and the risk of future
cerebrovascular events was found when shunt size was dichotomized
as small or moderate vs. large.308 However, three recent studies have
shown that among adults who had had a cryptogenic stroke, closure
of a PFO with an ASA or large interatrial shunt was associated with a
lower rate of recurrent ischaemic strokes than medical therapy alone
during extended follow-up.309–311 However, PFO closure was associ-
ated with higher rates of device complications and AF.309–311
No specific imaging pattern has been associated with a causal role
of PFO in patients with ischaemic stroke.312 ASA, PFO size, shunt se-
verity, presence of Chiari network or Eustachian valve, and an atrial
septal hypermobility can be linked to a causal role of PFO.312–314
Of note, in patients with endocardial leads (endocardial pacemaker
and defibrillator), the presence of a PFO is associated with a greater
than threefold increased risk of ischaemic stroke/TIA.315
Mechanisms of paradoxical embolism
Right atrial thrombi: thrombi ‘in transit’ (paradoxical embolism). RA
thrombi are usually diagnosed in the setting of pulmonary embolism,
and have been identified in 7–18% of patients with pulmonary embol-
ism. RA thrombi are related to venous thromboembolic disease, as
the RA represents a transit zone on the pathway between the legs
and the pulmonary arteries.316 TOE shows mobile and freely moving
masses not attached to an intracardiac structure. When a systemic
thromboembolic event occurs, a paradoxical embolism should be
suspected.
Another condition more linked to systemic thromboembolism is
the thrombus straddling the PFO. It is diagnosed by TOE and appears
as an oblong echodensity trapped in the foramen ovale, with two dis-
tal extensions. It is best visualized on a short-axis view of the heart.
The thrombus is often described as long, mobile, and snake-shaped;
sometimes it prolapses into the right ventricle and/or LV through the
atrioventricular valves. This diagnosis of a thrombus straddling the
PFO is rarely made by TTE; however, TTE may document the conse-
quences of pulmonary embolism (dilated right cavities, paradoxical
septum, and arterial pulmonary hypertension). TTE may also show
serpentine thrombi in the LA and/or RA.317
In the setting of systemic embolism, the documentation of a
thrombus straddling the PFO confirms a paradoxical embolism. The
optimal choice of treatment remains challenged.317
.....................................................................................................
Recommendations for evaluation of atrial septal anomalies
(ASA, PFO)
In patients with cryptogenic stroke or TIA, PFO should be ruled out by
contrast TTE and, if contrast TTE is negative, on contrast TOE.
ASA is defined as a >10 mm excursion from the plane of the atrial sep-
tum or a combined total excursion right and left >_15 mm.
Contrast TOE is the reference method for defining a PFO. Contrast TTE
has a lower sensitivity than other techniques, including transcranial
Doppler. However, if contrast TOE is negative in the case of crypto-
genic stroke, a second method should be performed (i.e. contrast TTE
or transcranial Doppler).
At-risk PFO should be defined, based on the following: presence of an
ASA, PFO size, length of the tunnel, number of bubbles crossing the
interatrial septum (>_30 bubbles) (presence of Chiari network or
Eustachian valve can be linked to a causal role of PFO).
3D contrast TOE may provide additional information in assessing intera-
trial septal anatomy and localization of the right-to-left shunt.
Contrast TOE should be systematically performed before the indication
of a PFO closure and interpreted by the heart–brain team before any
decision.
3D, three dimensional; ASA, atrial septal aneurysm; PFO, patent foramen ovale;






















































































































Left atrial septal pouch. LASP is defined as incomplete fusion of the
cranial segment of the overlap between the septum primum and sep-
tum secundum, resulting in a recess opening into the LA in the ab-
sence of an interatrial shunt at rest or with Valsalva manoeuvre
release.318 LASP may serve as a nidus for thrombus formation, par-
ticularly in the presence of low flow states, and therefore predisposes
to thromboembolic events.318 LASP is best identified using a standard
bicaval view by TOE imaging, and 3D TOE may add incremental value
for detecting and characterizing LASP morphology.17 LASP generally
cannot be identified using TTE, whereas they can be detected using
either cardiac CT or MRI.319 A previous autopsy study reported a
prevalence of 39% among randomly selected patients with cardiovas-
cular disease,320 although subsequent studies have reported a lower
prevalence with a suspected decline with increasing age.321
Published case reports have speculated on a causal relationship be-
tween LASP and ischaemic stroke,319,322,323 and a number of retro-
spective studies have more closely examined this association.
However, results to date have been discordant (Supplementary data
online, Table S10).318,324–326 A retrospective case–control study of
187 patients aged >50 years undergoing TOE after presenting with is-
chaemic stroke found no significant association between the pres-
ence of LASP and ischaemic stroke after comparison with 157
stroke-free controls.318 A more recent study of 126 patients present-
ing with cryptogenic stroke undergoing TOE compared with 137
patients without stroke reported an association with LASP that was
significant after adjustment for multiple other stroke risk factors.321 A
systematic review pooling data from 516 ischaemic stroke patients
and 779 controls found no significant association.326
Figure 11 illustrates the use of multimodality imaging in the diagno-
sis of atrial septal abnormalities.
Valvular abnormalities
Mitral valve prolapse
Mitral valve prolapse arises as a result of myxomatous degeneration
of the valve tissues and presents on 2D TOE as a hernia or protrusion
measuring >2 mm in one or both of the LA mitral valve leaflets in sys-
tole, referred to as ‘floppy valve syndrome’ (morphological abnor-
mality), and coaptation of the two mitral leaflets posterior to the
mitral annulus mainly observed in the long-axis, parasternal longitu-
dinal view.327,328 The sensitivity and specificity of TOE for the detec-
tion of mitral valve prolapse are 87% and 97%, respectively.329
Higher values, approaching 100%, have been obtained using TOE330
and 3D echocardiography.331
A link between mitral valve prolapse and ischaemic stroke has
been described in young subjects, predominantly those aged
<45 years332 or with a diffuse-form prolapse (mitral, aortic, and tri-
cuspid) and valve thickening333,334 but, as yet, the attributable risk of
mitral valve prolapse to ischaemic strokes in young patients is very
low (0.14–0.6/100 patient-years).335
The mechanism of stroke in mitral valve prolapse is not clearly
understood. They may be caused either by platelet emboli forming
on splits in the valve endothelium and subendothelium conjunctive
tissue, or cruoric thrombi developing in the cul-de-sac formed by the
posterior mitral valve and the LA wall. They are most likely related to
the presence of other risk factors for embolism, primarily AF, which
may be paroxysmal and asymptomatic. High-risk echocardiographic
features in mitral valve prolapse are: >_5 mm valve thickening, valvular
dystrophy (redundancy), enlarged LA, >_mild mitral regurgitation, and
the presence of interatrial septal aneurysms.336
.................................................................................................
Recommendation on the evaluation of PFO and paradoxical
embolism
Contrast TTE should be performed or repeated in case of the occur-
rence of a TIA, ischaemic stroke, or peripheral embolism in patients
with documented venous thrombosis and/or pulmonary embolism.
TIA, transient ischaemic attack; TTE, transthoracic echocardiography.
Figure 11 Multimodality evaluation of atrial septal abnormalities.
2D TOE (left panel): (A) ASA and (B) PFO in the same patient, diag-
nosed using contrast TOE (57) during the Valsalva manoeuvre; (C)
thrombus within an atrial septal pouch. 3D TOE (right panel): (D)
entrapped thrombus through an ASA with a PFO; (E) entrapped
thrombus through a PFO in patient with acute pulmonary embol-
ism; (F) CMR: ASA on 2D SSFP imaging (Supplementary data online,
Videos S12–S14). 2D, two-dimensional; 3D, three-dimensional; ASA,
atrial septal aneurysm; CMR, cardiac magnetic resonance; CT, com-
puted tomography; PFO, patent foramen ovale; SSFP: steady-state




















































































































































Mitral annulus calcification is a very common (incidental finding) de-
generative process (detected at echocardiography in approximately
14% of cases).337 It mainly affects older people (>60 years), women,
and patients with hypertension, diabetes, chronic renal dysfunction,
or dysregulated mineral metabolism.338–340 Patients presenting with
mitral annulus calcification often have comorbidities such as endocar-
ditis, arrhythmia, systemic emboli, and aortic valve calcification.340 In
advanced cases, it may cause significant obstruction of LV inflow and
symptomatic mitral stenosis.
Mitral annulus calcification refers to a chronic inflammatory fibrous
calcification of the mitral annulus (endothelial dysfunction, lipids, and
calcium deposit in the fibrous ring of the mitral valve). No clear causal
relationship between ischaemic stroke and mitral annulus calcification
has been established because it is more a marker for generalized ath-
erosclerosis.338,339 However, occasionally, mobile plaques may be
clearly identified at the level of the calcified annulus by echocardiog-
raphy and, in those cases, the probability of a migration of calcified
emboli or thrombotic debris is much higher. Certain ischaemic
strokes may be related to an increased incidence of AF.337
Multimodality imaging with 2D, 3D, and Doppler echocardiography
(Figure 12) and CTA can delineate the extent and location of mitral
annulus calcification to help guide therapeutic strategies. Three semi-
quantitative grades of severity can be identified: mild (focal, limited in-
crease in echodensity of the mitral annulus), moderate (marked
echodensity involving one-third to one-half of the ring circumfer-
ence), or severe (marked echodensity involving more than half of the
ring, or with intrusion into the LV inflow tract). Multislice CT can bet-
ter quantify the severity of calcification. It is usually visualized on
echocardiography as an echodense shelf-like structure with an irregu-
lar, lumpy appearance involving the mitral valve annulus, with associ-
ated acoustic shadowing. Using 18F-sodium fluoride (calcification
activity) and 18F-fluorodeoxyglucose (inflammation activity) PET, mi-
tral annulus calcification has recently been shown to be characterized
by both calcification and inflammatory activity that increases propor-
tionally to the baseline calcification burden (highest baseline CT cal-
cium scores).341
Cardiac CT has been proposed in the evaluation of the extent and
location of mitral annular calcification.342
Aortic valve calcification and stenosis
Calcific aortic valve disease with or without stenosis is a very com-
mon feature, especially among older adults. The clinical precursors of
atherosclerosis are also risk factors for calcific aortic valve disease.343
Spontaneous embolic complications observed in calcific aortic valve
disease are rare and most often clinically silent, particularly owing to
the small size of the thrombi, which preferentially migrate to the ret-
inal artery.344 Rarely, larger emboli have been associated with calcific
aortic valve disease, mainly in procedural settings such as cardiac
catheterization and percutaneous intervention or heart surgery.345
TTE or TOE may rarely visualize small debris or mobile plaques at
the level of the valve leaflets or annulus, further reinforcing the po-
tential for an embolic event. Cardiac imaging techniques play a key
role in the study of calcific aortic valve disease by confirming the diag-
nosis and estimating its severity. Calcium scoring CT offers the advan-
tage of quantifying the calcium load at the valve level, which is
associated with the severity of aortic valve stenosis (>_2000 Agatston
units for men and >_1200 Agatston units for women to distinguish se-
vere from moderate aortic stenosis), and predicts poor prognosis
and disease progression.346,347
Giant Lambl’s excrescences and strands
Lambl’s excrescences (or fibrous filaments or strands) are thin, elon-
gated, mobile structures that arise opposite the contact surfaces of
cardiac valve leaflets. They are more commonly described on the mi-
tral valve (atrial surface), but are also described on the ventricular
side of the aortic valve, and can also be found on prosthetic valves
and, rarely, on native tricuspid and pulmonary valves.348 Two case-
controlled studies348,349 had discordant findings with respect to the
association between valvular strands and ischaemic stroke, although
both detected a relatively high prevalence in patients referred for ex-
ploration of cryptogenic stroke. Another case–control study350
involving 284 patients referred for evaluation after an ischaemic
stroke and 276 controls aged >60 years found a significantly
increased stroke risk in patients presenting with mitral valve strands
identified by TOE. These patients were monitored for a mean of
2.3 years and the risk of recurrent ischaemic stroke was not different
in those with or without strands (6% vs. 4.2% per patient-year, re-
spectively). The presence of mitral valve strands was not an inde-
pendent predictor of risk for this outcome. A recent case-control
study including 77 systemic lupus erythematosus cases and 26 age-
and sex-matched controls found a similar frequency of Lambl’s
excrescences between the two groups and no association with inci-
dent ischaemic stroke.351
See Supplementary data online, Videos S16.
Figure 12 Mitral annular calcifications on 2D TTE (short-axis
view) (see Supplementary data online, Video S15). 2D, two-dimen-
sional; TTE, transthoracic echocardiography.
.....................................................................................................
Recommendations for evaluation and treatment of minor and
putative sources of ischaemic stroke
Isolated and uncomplicated mitral valve prolapse should not be consid-











































































































Vascular imaging and contrast TTE/TOE are considered the first-line
tool in the search for a cardiac source of embolism (Figure 13). CT
and MRI are considered as alternative tools, and their indications are
described on a case-by-case approach:
• In the case of normal contrast TTE, cardiac rhythm (atrial tachyar-
rhythmia vs. sinus rhythm) should be taken into account.
• In patients with AF, contrast TTE can detect the presence of
thromboembolic risk markers (LA size, LA strain alteration, and
LVEF <40%). The indication for contrast TOE cannot be part
of a routine indication, except to answer a specific question or
for inclusion in a research protocol. Without TTE-derived
thromboembolic risk markers, contrast TOE indication is
mandatory.
• In the case of sinus rhythm (i.e. cryptogenic stroke), contrast
TOE and a Holter electrocardiogram are mandatory.
• In the case of abnormal contrast TTE, a minor cardiac source of
embolism has to be distinguished from a major cardiac source of
embolism.
• If a minor cardiac source of embolism is detected, contrast
TOE might be indicated: (i) if another potential cardiac source
of embolism (>20% of cases) is suspected; (ii) before percutan-
eous interatrial septum closure; and (iii) in the event of un-
equivocal results on contrast TTE.
• In the case of negative contrast TOE, a transcranial Doppler
is indicated. In case of a negative transcranial Doppler, a
Holter monitoring should be considered.
• If a major cardiac source of embolism is detected and is an un-
equivocal potential source of embolism, the indication of con-
trast TOE may be debatable. However, its input is indisputable
for the detection of potential cardiac sources of small size
(below the resolution of contrast TTE), such as atrial or LV
thrombosis, atrial or LV tumour, or valvular vegetation.
• When contrast TTE is equivocal, contrast TOE indication is
mandatory.
Conclusions
Cardiac embolism accounts for an increasing proportion of ischaemic
strokes, and the role of cardiac imaging (TTE with contrast, TOE
with contrast, MRI, and CT) is increasing (Supplementary data online,
Tables S11 and S12). Echocardiography constitutes the primary
choice for cardiac imaging after acute ischaemic stroke, with TTE and
TOE providing complementary information. Cardiac CT and MRI are
valuable alternatives in specific situations. AF remains the main car-
diac source of embolism, although the role and imaging characteris-
tics of LA/LAA dysfunction remain debatable (e.g. LAA geometry,
LAA dysfunction, LA strain, LA/LAA SEC). Improved imaging of aor-
tic atheromas (TOE > CT), ventricular thrombus (MRI > TTE), atrial
thrombus (TOE or CT > MRI), valvular masses (3D TOE > MRI or
CT) may lead to better aetiological work-up in patients with ischae-
mic stroke. Despite such a work-up, one-third of ischaemic strokes
have an unclear cause, leading to the concept of ESUS, secondary to
the so-called atrial cardiomyopathy. A thrombogenic atrial substrate
(LA/LAA anomalies in cellular components, geometry, and/or func-
tion) can lead to atrial thromboembolism. LA strain, MRI (LA fibro-
sis), biomarkers and echo-markers, and rhythm anomalies can be
further characterized. Atrial septal anomalies deserve careful examin-
ation to describe at-risk PFO and to discuss the indications of PFO
closure in patients with cryptogenic stroke, after in-depth discussion
and the ruling out of other possible causes, including occult AF
(Holter or prolonged rhythm monitoring, insertable cardiac moni-
tors). Patients with cryptogenic stroke constitute a heterogeneous
group, leading to therapeutic implications based on the potential
mechanism. The concept of ESUS deserves further refinement, be-
cause the results of the two studies on non-vitamin K antagonist oral
anticoagulants are negative.352,353
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Continued
Recommendations for evaluation and treatment of minor and
putative sources of ischaemic stroke
Mitral annulus and aortic valve calcifications should not be considered as
potential cardiac sources of embolism because both are incidental and
associated with other causes (e.g. aortic atheroma).
The significance of LASP for patients presenting with cryptogenic ischae-
mic stroke remains uncertain, and no recommendation can be made
regarding the management of ischaemic stroke patients with LASP.
Larger studies are needed to evaluate whether LASP is a risk factor for
ischaemic stroke.
Lambl’s excrescences are only weakly correlated with stroke risk. Their
discovery during work-up for a cryptogenic stroke should not discour-
age the search for another possible cause. It has no effect on patient
management.
LASP, left atrial septal pouch.
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69. Pagola J, González-Alujas T, Flores A, Muchada M, Rodriguez-Luna D, Seró L et
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